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ABSTRACT OF THE DISSERTATION

The role of astrocyte activation in infantile neuronal ceroid lipofuscinosis (INCL)
by
Shannon Lynn Macauley-Rambach
Doctor of Philosophy in Biology and Biomedical Sciences (Neurosciences)
Washington University in St. Louis
Dr. Mark S. Sands, Chairperson

Infantile neuronal ceroid lipofuscinoses (INCLs), or Batten Disease, is an
inherited neurodegenerative lysosomal storage disorder affecting the central
nervous system (CNS) during infancy or childhood.

Hallmark pathological

changes include accumulation of autofluorescent material, neuronal loss, cortical
thinning, and brain atrophy, which ultimately lead to cognitive deficits, motor
dysfunction, seizure activity, and blindness. INCL is the result of mutations in the
CLN1 gene leading to a deficiency in the lysosomal enzyme, palmitoyl protein
thioesterase 1 (PPT1). A mouse model of INCL, the PPT1-deficient (PPT1-/-)
mouse, was recently created by a targeted disruption in the CLN1 gene. The
phenotype of the PPT1-/- mouse is similar to that found in human INCL patients,
suggesting the PPT1-/- mouse is an authentic model of INCL.

Although the

clinical symptoms of disease are well described, the cellular mechanisms
underlying these pathological changes and functional deficits remain poorly
understood. Therefore, the first goal of this dissertation was to investigate the
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temporal-spatial progression of disease in a mouse model of INCL.

We

demonstrated a profound neuronal and glial involvement underlying both
physiological and functional deficits. From these studies, we also found the first
pathological change observed was the upregulation of glial fibrillary acidic protein
(GFAP), a marker of astrocyte activation, in the thalamus, cortex, and
cerebellum. Focal regions of GFAP upregulation were an accurate predictor of
future sites of neuronal loss.

Since astrocyte activation is both helpful and

harmful to an injured CNS, the second aim of this dissertation was to investigate
the role of astrocyte activation in a mouse model of INCL using the GFAP-/-,
Vimentin-/- mice.

We demonstrated that astrocyte activation, as defined by

GFAP upregulation, plays a protective role in INCL.
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Chapter One

Introduction
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INTRODUCTION
Lysosomal Storage Diseases: An Overview
Lysosomal storage diseases (LSDs) are a group of rare, inherited
disorders involving both the visceral tissues and central nervous system (CNS) of
affected patients (Hers, 1965; Neufeld, 1991). There are greater than 45 distinct
metabolic disorders in total. LSDs affect approximately 1 in 5,000 live births,
making these disorders one of the most common childhood genetic diseases
(Meikle et al., 1999).
Each LSD is a discrete genetic disorder caused by a single gene mutation.
In all cases, the genetic mutation of a particular protein causes a disruption in
normal lysosomal function (Scriver, 2001). Most of the disorders are transmitted
through autosommal recessive inheritance, but a subset of LSDs is X linked. The
main function of the lysosome is the degradation of macromolecules into simpler
metabolites. Most LSDs are due to defects in soluble lysosomal enzymes that
are responsible for the catabolism of macromolecules. The mutations lead to the
reduction (>90%) or complete ablation of enzyme activity for that specific protein.
The remainder of LSDs is caused by mutations in key lysosomal membrane
proteins, proteins involved in lysosomal enzyme trafficking, or proteins
responsible for lysosomal enzyme activation (Neufeld, 1991; Winchester, 2004).
Regardless of the function of a given protein, most LSDs result in the
accumulation of undigested substrates in the lysosomal compartment. As the
undegraded product steadily accumulates within the organelle, both the size and
number of lysosomes within a cell increases. Upon microscopic inspection, this
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lysosomal accumulation gives the cell
and

its

cytoplasm

a

A

B

“foamy”

appearance; a hallmark characteristic
of LSD pathology (Figure 1). Although
the

mechanism

(Ballabio

and

is

still

unknown

Gieselmann,

Figure 1. Lysosomal accumulation in a
model of LSD.
Notice the lysosomal
accumulation and distension (arrows) in a
diseased neuron (B) compared to a WT
neuron (A).

2009),

accumulated substrates interfere with

normal cellular processing, ultimately affecting the function of vital organs such
as the brain, kidneys, liver, lungs, spleen, and heart (Macauley and Sands,
2009b; Neufeld, 1991; Scriver, 2001). The clinical signs associated with LSDs
can include organomegally, skeletal deformities, pulmonary insufficiencies,
immunologic abnormalities and cardiac defects.

In addition to these systemic

problems, CNS involvement occurs in 75% of all LSDs.

This subset of affected

patients present with some or all of the following neurologic symptoms:
developmental regression, visual and hearing deficits, mental retardation,
seizures, motor deficits, speech impairment, and other behavioral abnormalities
(Hoffmann and Mayatepek, 2005; Sands and Haskins, 2008; Walkley, 1998).
LSDs can affect patients as early as within the first year of life, or alternatively,
they can present in adulthood. Regardless of onset, each disorder is progressive
in nature, with a complex set of clinical maladies and ultimately premature death.
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Neuronal Ceroid Lipofuscinoses (NCLs)
Neuronal ceroid lipofuscinoses (NCLs), or Batten Diseases, are a group of
autosomal recessive lysosomal storage disorders (LSDs) typified by prominent
CNS involvement. As a class of disorders, the overall incidence is approximately
1:12,500 live births and represents the most common inherited pediatric
neurologic disorders worldwide (Bennett and Hofmann, 1999; Goebel and
Wisniewski, 2004; Hofmann and Peltonen, 2001).
disorders was historically based on the age of onset.

Classification of these
Infantile (INCL), late-

infantile (LINCL), and juvenile (JNCL) forms referred to cases affecting children;
however, rare forms with an adult onset (ANCL) were also described. Recently,
the use of modern genetic tools has led to a more accurate classification of the
various forms of NCL. To date, there are eight different forms of Batten Disease
resulting from mutations in separate genes, CLN1 through CLN8 (Cooper, 2003;
Goebel and Wisniewski, 2004). Although the metabolic function of many of these
gene products remains unclear, it is known that CLN1, CLN2, and CLN5 encode
soluble lysosomal enzymes while the remaining CLN genes encode lysosomal
membrane proteins.
Although the age of onset, disease progression, and age of death vary in
each form of NCL, there are characteristics common to all forms of NCL. The
clinical course of disease is progressive and includes blindness, epilepsy, mental
retardation, and motor deficits (Hofmann and Peltonen, 2001; Rider and Rider,
1988; Santavuori, 1988; Santavuori et al., 1974). A histological finding common
to all the NCLs is the intracellular accumulation of autofluorescent substrates. To

4

date, the composition of this storage product remains largely unknown. The
accumulation of storage material coincides with pathological changes such as
widespread neuronal loss, retinal degeneration, cortical thinning, and overall
brain atrophy (Wisniewski et al., 1988). More recently, astrocyte proliferation and
microglia activation were described in both patients with NCL and animals
models of disease. Although the CNS pathology and functional impairment is
well documented in these diseases, it still remains unclear how the two are
related.

Infantile Neuronal Ceroid Lipofuscinosis (INCL)
Of the eight distinct genetic variants currently described, infantile neuronal
ceroid lipofuscinosis (INCL) is the most rapidly progressing form of NCL
(Hofmann et al., 1999; Hofmann and Peltonen, 2001; Vesa et al., 1995).
Clinically, patients with INCL appear asymptomatic at birth and development
proceeds normally until 6-12 months of age. By 12 months of age, affected
children begin to show signs of developmental regression, including mental
retardation, microcephaly, and motor deficits (Hofmann et al., 1999; Hofmann
and Peltonen, 2001; Santavuori et al., 1974; Vesa et al., 1995).
impairment is often the first clinical sign of INCL.

Visual

Typically, visual defects

emerge about one year of age, which lead to blindness by age 2. Myoclonic
jerks appear between 16 to 24 months of age, which is concurrent with changes
in electroencephalography (EEG). Specifically, there is decreased amplitude or
flattening of background EEG activity by 2 years of age, which progresses to an
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inactive EEG by 3-4 years of age (Haltia et al., 1973a; Haltia et al., 1973b; Haltia
et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al., 1997). The average
age of death is 6 years of age, but some children survive until adolescence.
At autopsy, the CNS pathology is remarkable (Haltia et al., 1973a; Haltia
et al., 1973b; Haltia et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al.,
1997). There is an overall brain atrophy, mostly due to thinning of the cerebral
cortex.

The cerebral cortex is denuded of neurons and replaced by

macrophages, activated microglia and reactive astrocytes. The cerebellar cortex
is also atrophic due to a loss of both granule cells and Purkinje cells. Neuronal
cell loss is present in subcortical structures, with the thalamus most severely
affected and the brain stem, hypothalamus, and subthalamus relatively spared.
In addition to the neurodegeneration and astrocytosis in the cerebrum and
cerebellum, there is a nearly complete loss of myelin at the end stage of disease,
with myelin levels being 2% of normal.
The cellular pathology underlying the gross anatomical changes is severe
as well. Like other forms of NCL, autofluorescent accumulation is a hallmark of
INCL.

The storage product, when examined by electron microscopy, is

composed of granular osmiophilic deposits (GRODs) localized to the lysosome.
Although the exact composition of GRODs is poorly understood, biochemical
studies identified the storage material to be 43% protein and 35% lipid. Of the
proteins extracted, three major products were identified- Saposins A and D
(SAPs A and D) and glial fibrillary acidic protein (Haltia et al., 1995; Tayama et
al., 1992; Tyynela et al., 1993). Interestingly, the major constituent of storage
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accumulation in other NCLs, subunit C of mitochondrial ATPase (Palmer et al.,
1992), is not found in GRODs from INCL patients. Although it is important to
identify the storage products within disease cells, the role SAP A and D or GFAP
plays in disease pathogenesis remains unknown.
Infantile neuronal ceroid lipofuscinosis is the result of mutations in the
CLN1 gene, which encodes the lysosomal enzyme, palmitoyl protein thioesterase
1 (PPT1; (Das et al., 1998; Hofmann et al., 2002; Mitchison et al., 1998;
Mitchison et al., 2004; Vesa et al., 1995). The human cDNA encoding PPT1
consists of a 918 base pair open reading frame flanked by a short 14 base pair
5’-untranslated region and a 1388bp 3’-untranslated region (Camp et al., 1994;
Hofmann and Peltonen, 2001). In the 306 amino acid residues of the human
protein, the catalytic triad, consisting of serine, aspartine, and histine, at base
pairs 115, 233, and 289, respectively, is necessary and sufficient for enzymatic
activity (Calero et al., 2003; Schriner et al., 1996). Two isoforms of human PPT1
exist as monomers with molecular weights of either 37kDa or 35kDa, depending
on glycosylation.

Functionally, PPT1 is a soluble lysosomal hydrolase that

cleaves fatty acid side chains from lipid-modified proteins.

More specifically,

PPT1 acts at the thioesterase cleavage site of membrane bound, palmitoylated
proteins once targeted for degradation by the lysosome. The optimum pH for
PPT1 is quite broad and depends upon the substrate.

PPT1 is ubiquitously

expressed throughout the CNS and viscera with the highest levels present in
brain and testes. Within the CNS, in situ hybridization experiments demonstrated
that PPT1 expression is both developmentally and spatially regulated (Haltia et
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al., 1973a). High levels of enzyme are present in the cerebral cortex, CA1-CA3
of the hippocampus, dentrate gyrus, and the hypothalamus. Not surprisingly,
these regions are the ones most severely affected by disease pathogenesis in
INCL. It is hypothesized that without the removal of fatty acid residues from
palmitoylated proteins, small peptides become resistant to degradation and form
large aggregates, a process similar to that found in Prion and Alzheimer’s
Diseases.
Infantile neuronal ceroid lipofuscinosis is a debilitating, neurologic disease
with a complex set of psychomotor dysfunctions due to widespread
neurodegeneration. Besides supportive care for patients, there is currently no
therapy or cure for INCL.

Further work needs to be done to increase our

understanding of disease progression in INCL in order to identify appropriate
targets for therapeutic intervention.

PPT1-deficient mouse
Recently, a mouse model of INCL, the PPT1-deficient (PPT1-/-) mouse,
was created by disrupting the PPT1 gene (Gupta et al., 2001). A neomycin
resistance cassette was introduced into exon 9 of the murine PPT1 gene
introducing a premature stop codon in the PPT1 protein. Immunoblot analysis
coupled with enzymatic assays demonstrated the absence of both PPT1 protein
and activity, respectively, making a functionally null mutant. The PPT1 mutation
was subsequently backcrossed onto the C57Bl/6 brain for 10 generations to
develop a congenic model of INCL (Griffey et al., 2005).
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The phenotype of PPT1-/- mice mirrors the clinical course of INCL. PPT1/- mice have a decreased life span compared to littermate controls where 50% of
mice die by 7 months of age and 100% mice are dead by 10 months (Bible et al.,
2004; Griffey et al., 2004; Gupta et al., 2001). Initial studies were performed to
characterize the pathology and behavioral deficits at 7 months, an end stage of
disease. These studies demonstrated that the mice develop similar cognitive,
motor, visual, and physiological deficits as patients with INCL.

Initial

characterization studies described gait abnormalities in PPT1-/- mice at 4-5 mos.
of age, which progressed to hind limb paralysis by 7 mos.

Seizure activity,

largely myoclonic jerks, was observable at an end stage of disease. EEGs of 7month PPT1-/- mice demonstrated an abnormal background (interictal) pattern of
activity in addition to seizures (Griffey et al., 2006). Electroretinograms (ERGs),
a surrogate test for visual function, were abnormal as early as 2-3 mos. and
worsened with age, demonstrating retinal deficits within the PPT1-/- mice. Taken
together, these data demonstrate that PPT1-/- mice show similar functional
deficits as those observed in patients with INCL (Griffey et al., 2005).
In addition to functional changes, the underlying pathology in the PPT1-/mouse is similar to that seen in affected patients at a terminal stage of disease
(Bible et al., 2004; Griffey et al., 2004; Gupta et al., 2001). Overall, brains of
PPT1-/- mice were significantly smaller than normal littermates.

Differential

atrophy of various brain regions was observed with cortical areas most severely
affected.

On a cellular level, widespread accumulation of autofluorescent

material, specifically GRODs, was observed in PPT1-/- mice There is variation in
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the temporal and spatial accumulation of GRODs, but by 7 months the entire
brain was grossly affected (Galvin et al., 2008). Widespread neurodegeneration
was observed throughout the neuraxis. In addition to changes observed in the
neuronal population of PPT1-/- brains, abnormalities in the glia were also
described. Astrocyte reactivity and microglial activation was remarkable by 7
months of age (Bible et al., 2004).
Although INCL is considered primarily a neurodegenerative disease, the
accumulation of GRODs is present in systemic tissues of the mouse, such as
liver, kidney, and heart (Galvin et al., 2008). Contrary to other LSDs, the clinical
consequences of systemic accumulation of GRODs appear to be mild. However,
there are significant cardiac changes such as left ventricular hypertrophy and
dilation of the ascending aorta. These changes are consistent with the visceral
symptoms observed in children with INCL.
Taken together, the PPT1-/- mouse is an authentic murine model of INCL.
Given the behavioral and physiological abnormalities observed, disease
progression in the PPT1-/- mice mirrors that of the human course of disease.
Similarly, the cellular pathology in the PPT1-/- mice at an end stage of disease is
similar to the pathology described at autopsy in patients with INCL.

Goals of thesis
Given the similarities between the murine model and human form of INCL,
it is possible to further investigate the cellular pathology and functional deficits in
the PPT1-/- mice to gain insights into the course of human disease. The goals of
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this thesis were to utilize the PPT1-/- mouse to obtain a better understanding of
the disease progression associated with INCL and ultimately, develop novel
therapies for the treatment of this disorder.
Thus, the first aim of this thesis was to investigate the temporal and spatial
progression of CNS disease in the congenic PPT1-/- mouse.

Based on the

findings at autopsy in INCL patients as well as the preliminary data from the
PPT1-/- mouse, we hypothesized that the progression of disease in the CNS
involves both the neuronal and glial populations throughout the neuraxis. We
hypothesized that the cellular pathology would correlate both spatially and
temporally with the functional changes associated with INCL.

Thus,

characterization studies need to include not only the forebrain of PPT1-/- mice
but also the hindbrain, where movement centers are located. Furthermore, we
sought to evaluate the time course of functional deficits in the PPT1-/- mouse,
specifically in regards to physiology (seizure activity) and behavior (motor
deficits).
Based on the findings from our characterization studies (outlined in
Chapter 2), we identified astrocyte activation, as defined by GFAP upregulation,
as an early and prominent feature of this disease. More specifically, our studies
demonstrated that astrocyte activation is the first pathological change observed
in the PPT1-/- brains, prior to any signs of neurodegeneration or functional
deficits. Therefore, the second aim of this thesis was to investigate the role of
astrocyte activation in the disease progression of INCL.
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Chapter Two

Characterization of the forebrain & hindbrain
pathology in the PPT1-/- mouse,
a mouse model of INCL

This chapter is adapted from the following manuscripts:
Macauley SL, Wozniak D, Kielar C, Tang Y, Cooper JD, and Sands M.
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1
deficient mouse. Exp. Neurol. 2009 May; 217(1):124-35.
Kielar C., Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA,
Wong M, Sands MS, and Cooper JC. Neuron loss occurs in the thalamus before
the cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol
Dis. 2007 Jan; 25(1):150-62.

12

Introduction
Infantile neuronal ceroid lipofuscinoses (INCLs), or Batten Disease, is an
inherited neurodegenerative lysosomal storage disorder affecting the central
nervous system (CNS) during infancy or childhood (Bennett and Hofmann, 1999;
Goebel and Wisniewski, 2004; Hofmann and Peltonen, 2001). INCL is the result
of mutations in the CLN1 gene leading to a deficiency in the lysosomal enzyme,
palmitoyl protein thioesterase 1 (PPT1; (Das et al., 1998; Hofmann et al., 2002;
Mitchison et al., 1998; Mitchison et al., 2004; Vesa et al., 1995).

Hallmark

pathological changes in the CNS include accumulation of autofluorescent
material, neuronal loss, cortical thinning, and brain atrophy, which ultimately lead
to cognitive deficits, motor dysfunction, seizure activity, and blindness (Hofmann
et al., 1999; Hofmann and Peltonen, 2001; Santavuori et al., 1974; Vesa et al.,
1995) (Haltia et al., 1973a; Haltia et al., 1973b; Haltia et al., 1995; Hofmann and
Peltonen, 2001; Vanhanen et al., 1997). The neurodegeneration associated with
INCL in humans is well documented; however, it remains unclear how the cellular
pathology, in either neurons or glia, within the CNS contributes to physiological
deficits and behavioral impairment. Further investigation into the specific cellular
pathology of neurons and astrocytes is necessary to better understand INCL and
develop effective therapies for this disorder.

Initial characterization studies
A mouse model of PPT1-deficiency was created by a targeted disruption
in the CLN1 gene (Gupta et al., 2001).
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The initial characterization was

performed at an end stage of disease and demonstrated that the PPT1-deficient
mouse (PPT1-/-) shares many of the histological and clinical features of INCL
(Bible et al., 2004; Griffey et al., 2004; Griffey et al., 2005; Kielar et al., 2007).
Although mice develop normally from birth, premature death occurs by 8.5-9
months. Phenotypically, these mice suffer from blindness (Griffey et al., 2005),
seizures (Griffey et al., 2006; Kielar et al., 2007), cognitive deficits, and motor
dysfunction (Griffey et al., 2004; Griffey et al., 2006) at the end stage of disease.
These behavioral deficits are mirrored in children affected by INCL.
Upon gross examination of the PPT1-/- brains, Bible et al. (2004)
described an overall brain atrophy at 7 mos. of age. The affected mice have a
20-25% decrease in brain weight (Bible et al., 2004; Griffey et al., 2004)
compared to wildtype (WT) controls.

Although an overall decrease in brain

mass occurs in the PPT1-/- mouse, the extent to which certain areas are affected
differs from region to region. For example, a significant decrease in brain mass
was present in the cortex, thalamus, striatum, and hippocampus of PPT1-/- mice;
areas similarly affected in patients with INCL. The greatest volumetric change
was observed in the thalamus (i.e. 46% decrease), while the cortex and striatum
suffered a 35% and 30% reduction, respectively.

Furthermore, decreases in

cortical thickness varied based on the region of cortex investigated. Although
decreases in cortical thickness were apparent in numerous cortical areas (i.e.
motor, visual, somatosensory, and entorhinal cortex), the visual cortex and
somatosensory cortex were the most severely affected.
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Similar to patients with INCL, the CNS atrophy described is the result of
neuronal loss throughout the neuraxis of PPT1-/- brains. There is a significant
decrease in neuron number in both the cortex and hippocampus, most notably
within the interneuron population. Concurrent with the neuronal loss, there is an
increase in autofluorescent accumulation in the cortex, striatum, and cerebellum
of PPT1-/- brains. Although autofluorescent accumulation is a hallmark of INCL,
there is no causal link between neuronal hypertrophy due to autofluorescent
accumulation and neuronal death in the PPT1-/- mouse.
Concurrent with the characterization of the neuronal pathology, initial
studies investigated glial reactivity as well. In a 7 mo. PPT1-/- mouse, there is a
significant increase in both astrocyte activation (i.e. GFAP upregulation) and
microglial reactivity (i.e. F4/80 upregulation) in the cortex, hippocampus, and
striatum.

This demonstrates that neuroinflammation plays a role in the

pathogenesis of INCL, a phenomenon similarly described in human patients.
Initial characterization studies demonstrated that the phenotype of the
PPT1-/- mouse mirrored the behavioral deficits and cellular pathology described
in INCL patients at the end stage of disease.

Based on these findings, we

believe the PPT1-/- mouse is a valuable tool for investigating the disease
pathogenesis of INCL. Although the pathology of INCL patients at autopsy is
well described, it remains unclear how a genetic mutation, such as a CLN1
mutation, can evolve into such a debilitating, neurologic disease. Thus, studies
investigating the temporal-spatial progression of cellular pathology and
behavioral deficits should be employed to gain a better understanding of INCL.
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Aims of temporo-spatial characterization studies
The research aims seeking to further characterize the PPT1-/- mice were
two fold. First, our primary goal in these studies was to investigate the disease
progression in the cerebellum. Although profound motor deficits and cerebellar
pathology is described in patients with INCL, the initial characterization studies in
the PPT1-/- mouse did little to investigate the underlying pathology in the
hindbrain. Apart from a brief description of gait abnormalities and qualitative
reports of Purkinje cell loss in the PPT1-/- mouse, no additional investigation of
cerebellar pathology or motor deficits was performed. In addition to the autopsy
information from INCL patients, gene therapy studies in PPT1-/- mice
demonstrated that the most efficacious gene therapy strategy for the treatment of
INCL occurred when viral vectors were targeted to the cerebellum in combination
with the forebrain. Again, these data suggests the disease is not restricted to the
forebrain and further investigation of cerebellar pathology is warranted. Thus,
our primary goal was to perform a time course investigating the cellular pathology
and functional deficits associated with the cerebellar disease. In this study, we
determined the temporal changes in cellular pathology in both neurons and glia.
Concurrently, we quantified the progression of motor dysfunction.

Taken

together, these studies provide insight into the disease pathogenesis of INCL
cerebellum and its relationship to motor function (Macauley et al., 2009).
The second aim of our characterization studies focused on expanding the
initial descriptions of pathology and behavioral deficits localized to the forebrain.
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This study was carried out in collaboration with Catherine Kielar and other
members of Dr. Jonathan Cooper’s laboratory at Kings College, London (Kielar
et al., 2007). Although the descriptions of forebrain pathology at an end stage of
disease in the PPT1-/- mice were thorough, a temporal investigation of pathology
and functional deficits would provide insight into the evolution of disease in INCL.
A summary of results from this study is also included in Chapter 2.

Methods
PPT1-/- Mice
PPT1-/- mice were created as previously described on a mixed
background (Gupta et al., 2001). Subsequently, the mice were bred to C57Bl/6
mice for 10 generations to produce a congenic strain (Griffey et al., 2004).
Wildtype (+/+) or PPT1- deficient (-/-) mice were generated by either
heterozygous (+/-) or homozygous (-/-; +/+) matings at Washington University
School of Medicine by M.S.S. Mouse genotype was determined by a PCR-based
assay. Both male and female PPT1-/- mice and normal littermates (+/+) were
used in this study. Animals were housed under a 12:12 hour light:dark cycle and
were provided food and water ad libitum. All procedures were carried out under
an approved IACUC protocol from Washington University School of Medicine.
Cerebellar Weights
Seven month PPT1-/- (n=6) and wildtype littermates (n=5) were sacrificed
via CO2 asphyxiation and the brains harvested by a researcher blinded to
genotype and age. A sharp knife was inserted coronally into the transverse sinus
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to separate the cerebellum from the forebrain. Similarly, a coronal cut was made
immediately posterior to the cerebellum, separating the cerebellum from the
medulla and spinal cord. Care was taken to ensure that the cut was flush with
the back of the cerebellum. Each cerebellum was weighed using an analytical
balance and group differences in weights were analyzed using an independent
groups t test.
Quantification of Purkinje cells
Congenic PPT1-/- mice (n=3-6 per time point) and wildtype littermates
(n=3-4 per time point) at 1, 3, 5, 6, and 7 mo. of age were used in this study.
Briefly, mice were sacrificed via CO2 asphyxiation, brains removed and post-fixed
for 48 hours in 4% paraformaldehyde in phosphate buffered saline (PBS).
Cerebella were separated from the forebrain and bisected in the sagittal plane
about 1 mm off midline. The larger piece was embedded sagittally in paraffin
and sectioned at 5µm through the midline.

Sections were stained with

hematoxylin & eosin (H&E). Counts of surviving Purkinje cells were made from
midsagittal sections through the vermis for each lobe.

Purkinje cells were

counted if they possessed a well-defined cytoplasm and nucleus with the
presence of a distinct nucleolus.

Purkinje cells undergoing degeneration

possessed a shrunken, pyknotic appearance with irregular margins and were not
counted. The number of healthy Purkinje cells was recorded for each lobule (I
through X) of the PPT1-/- and wild type cerebellum. For statistical analysis, data
from wild type mice at the various ages counted (1-7 mos.) were collapsed and
treated as a single wild type group. Previous work as (Macauley et al., 2008b)
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well as data from this study demonstrated that Purkinje cell counts do not differ
significantly over this age range. The Purkinje cell count data were analyzed by
a repeated measures ANOVA model containing one between-subjects variable
(groups) and one within-subjects variable (lobes), and subsequent pairwise
comparisons. Bonferroni correction was used to maintain alpha levels at 0.05
when multiple comparisons were conducted.
Quantification of the Granular cell layer
To examine granule cell survival within lobule IV/V of the cerebellum, we
used StereoInvestigator software (MicroBrightField Bioscience, Williston, VT) to
obtain unbiased optical fractionator estimates of granule cell number from H&E
stained sections. Cells were sampled using a series of counting frames
distributed over a grid superimposed onto the section, with a random starting
section chosen, followed by every fourth section thereafter. The sizes of the
‘sampling grid’ and of the ‘dissector frame’ used in this study were 250x160µm2
and 20x20µm2 respectively. Only clearly identifiable cells that fell within the
dissector frame were counted, using a x100 oil objective.
The statistical significance of differences between genotypes of all
quantitative data was assessed using a one-way ANOVA (SPSS 11.5 software,
SPSS Inc, Chicago, IL), with statistical significance considered at p< 0.05. The
mean coefficient of error (CE) for all individual optical fractionator and Cavalieri
estimates was calculated according to the method of Gundersen and Jensen
(1987) and was less than 0.08 in all analyses.
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Immunohistochemistry for neuronal, astrocytic, & microglial markers
PPT1-deficient mice and wildtype littermates were sacrificed via CO2
aphyxiation for immunohistochemistry at 1, 3, 5, 6 and 7 months of age. The
brains were removed, fixed in 4% paraformaldehyde in phosphate buffer, and
cryoprotected with 30% sucrose in tris-buffered saline (TBS).

Brains were

sectioned in the sagittal plane through the vermis (20µm) using a freezing
cryostat.
antibodies:

Adjacent, free floating sections were stained with the following
rabbit

anti-glial

fibrilllary

associated

protein

(GFAP;

1:200

ImmunoStar, Inc.), rabbit anti-S100ß (1:200; Abcam), rat anti-F4/80 (1:100;
Serotec), mouse anti-calbindin (1:1000; Sigma), guinea pig anti-GLAST (1:2000;
Chemicon) rabbit anti-GLT1 (1:100; Santa Cruz), and rabbit anti-glutamine
synthetase (GS; 1:200 Santa Cruz).

Briefly, sections were washed in tris-

buffered saline (TBS), incubated in 1% H2O2 (Sigma) to quench endogenous
peroxidase activity, and rinsed thoroughly in TBS. The tissue was blocked for 1
hour in 10% normal goat serum (NGS; Sigma), 0.25% Triton X-100 in TBS.
Sections were incubated overnight at 4˚C in primary antibodies in 5% NGS, 0.2%
Triton X-100 in TBS. The following day the sections were rinsed in TBS and
incubated in secondary antibodies (1:200; Vector Labs) in 10% NGS, 0.1% Triton
X-100 in TBS for 75 minutes. The tissue was rinsed in TBS and then incubated
in a peroxidase conjugated avidin-biotin complex (1:200; Vectastain Elite ABC kit
from Vector Labs) for 1 hour at RT. Antibody immunoreactivity was visualized
with 3’-3’ diaminobenzidine and H2O2 (DAB kit; Vector Labs) in TBS. Sections
were dehydrated and coverslipped.
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DeOlmos Cupric Silver Staining
Six, 7 and 8 mo. old PPT1-/- mice (n=2 per time point) and wildtype
littermates (n=1-2 per time point) were deeply anesthetized with euthasol and
transcardially perfused with 4% paraformaldehyde in sodium cacodylate buffer.
The brains were removed and post-fixed for 48 hours.

Each brain was

embedded in a gelatin-based matrix (Switzer, 2000) and serial coronal sections
(35 µm) were cut on a freezing microtome by Neuroscience Associates
(Knoxville, TN).

Neuronal degeneration was visualized by staining with a

modified cupric silver method of DeOlmos (DeOlmos & Ingram, 1972; Switzer,
2000). A matrix of PPT1-/- and WT brains at identical levels in the coronal plane
were stained simultaneously. Every sixth section (210 µm interval) was stained
with the silver method and adjacent sections stained with H&E.
Luxol Fast Blue & PAS Stain
Seven-month-old PPT1-/- and wildtype littermates were sacrificed and
sectioned at 20µm as described above. Every 12th section throughout the vermis
was stained with luxol fast blue and Periodic-acid Schiff stain.
TUNEL Staining
TUNEL staining was performed on sagittal sections throughout the
cerebellum of PPT1-/- mice and wildtype littermates at 1, 3, 5, 6, and 7 months of
age using the Apoptag Apoptosis Detection Kit (Milipore Corp) per the
manufacturers instructions. Briefly, sections were warmed to room temperature
(RT) and treated with proteinase K (20µg/ml) for 15 minutes at RT. Immediately
following, endogenous peroxide was quenched with 1% hydrogen peroxide in
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methanol.

After sections were incubated in equilibration buffer for 1 minute,

working strength terminal deoxynucleotidyl transferase (TdT) enzyme was added
to the tissue and incubated in a humidified chamber at 37˚C. After a 60-minute
incubation, the reaction was stopped by the addition of working strength
stop/wash buffer for 10 minutes. An anti-digoxigenin conjugate was placed on
each specimen for 30 minutes and the reaction visualized with DAB substate.
The

tissue

was

counterstained

with

nuclear

fast

red.

Rotarod Testing
Congenic PPT1-/- mice (n=11-14 mice per group) and wildtype littermates
(n=11-14 mice per group) were tested on the constant speed rotarod (2.5 rpms)
at 1, 3, 5, 6, and 7 months of age. Latency to fall served as the dependent
variable and trials lasted a maximum of 60 s. At each age, mice received three
test sessions where each session included a pretest trial on a stationary rod,
followed by two test trials on the constant speed rotarod. To combat the effects
of training, only the last test session was used in computing statistical differences
with the previous two trials treated as training. A repeated measures ANOVA,
including one between-subjects variable (genotype) and one within-subjects
variable (age), was the main analysis conducted on monthly performance.
Additional analyses (independent groups and paired t test, respectively) were
performed on 1- and 7- month time points due to smaller sample sizes at these
ages.
Seizure Activity
C57Bl/6 controls (n = 4) and PPT1−/− mice at 6 (n = 4), 6.5 (n = 6), 7 (n =
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6) and 7.5 (n = 7) months of age were monitored for seizure activity and interictal
EEG activity using simultaneous video and EEG recordings (Griffey et al., 2006).
Briefly, each mouse was implanted with four epidural screw electrodes two days
prior to monitoring. Each monitoring session consisted of a continuous 48-hour
period. During each session, mouse behavior was captured via video monitoring
while EEGs were recorded using a computer interface and AxoScope software
(Molecular Devices, Sunnyvale, CA).

Seizures were identified using both

behavioral and EEG recordings. The number of animals with seizures, the
number of seizures per animal, and seizure duration will be counted for each
animal during each monitoring period. Statistical analysis was performed using
Kruskal–Wallis non-parametric ANOVA. Additionally, the background EEG was
scored by a board certified neurologist blinded to genotype. For analysis of the
interictal EEG back- ground, one-minute segments obtained from every 4 h of the
48 h EEG record were randomly selected and graded with a previously described
scale (Griffey et al., 2006) comprising: Grade 1 (normal)—normal background
theta rhythm with no spikes, Grade 2 (mildly abnormal)—mostly normal
background with some epileptiform spikes, Grade 3 (moderately abnormal)—
mostly abnormal background with frequent epileptiform spikes, Grade 4 (severely
abnormal)—burst-suppression pattern. A mean interictal EEG grade was
calculated for each genotype, and statistical comparisons were made using
ANOVA with Tukey–Kramer multiple comparison post hoc test.
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Results from Cerebellar Study
Cerebellar Weights
Upon gross inspection at 7 mo. of age, the PPT1-/- cerebella appeared
smaller than aged matched wildtype littermates (Figure 1A).
of

PPT1-/-

cerebella

was

0.076g

(SEM±0.0054)

The mean weight

compared

to

0.112g

Figure 1. An overall atrophy is observed in the PPT1-/- cerebellum at 7 mo. of age.
(A) Representative images of PPT1-/- and wildtype cerebella. Notice the size
differential between the mutant and wildtype control. (B) Quantification of the cerebellar
weights in PPT1-/- (n=5) and wildtype mice (n=5) revealed a statistically significant
decrease in cerebellar mass in PPT1-/- mice compared to wildtypes (p<0.002).

(SEM±0.0022) for normal mice. At an end stage of disease (7 mo.), analysis of
cerebellar weights (Figure 1B) demonstrated a significant loss of mass in the
PPT1-/- mice, [t(9) = 5.77, p < 0.0005].
deOlmos Cupric Silver Staining
Silver staining was performed on 6, 7, and 8 mo. PPT1-/- mice and
wildtype controls (Figure 2). Representative images of the anterior lobes of the
cerebellum in the coronal plane are shown in Figure 2. As PPT1-/- mice aged,
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Figure 2. DeOlmos cupric silver degeneration staining in PPT1-/- mice. (A-D)
Representative coronal images of silver staining in the anterior cerebellum of 7 mo. WT (A), 6
mo. PPT1-/- (B), 7 mo. PPT1-/- (C), and 8 mo. PPT1-/- mice (D). Notice the overall increase in
silver staining as the PPT1-/- mice age, most notably within the cerebellar white matter. (E)
Higher magnification image of the 7 mo. PPT1-/- cerebellum. In addition to the cerebellar white
matter, silver stained parasagittal bands, or blackened stripes, are visualized in the molecular
layer in the cerebellar cortex. Locator boxes identify the areas magnified in subsequent panels.
(F & G) High magnification of parasagittal banding found in an individual folia of PPT1-/- mice at
7 mo. The banding seen in the molecular layer is staining of the dendritic arbors of diseased
Purkinje cells. Blackened debris litters the Purkinje cell layer, most likely due to dying Purkinje
cells. (H) High magnification of a degenerating Purkinje cell, with a blackened soma and
dendritic arbor. (I) High magnification image of the cerebellar white matter tracts contains
degenerating efferent and afferent projections to the cerebellar cortex. Degenerating axons
represent the sole output of the PPT1-/- cerebellum.
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there was a progressive increase in neurodegeneration as visualized by silver
staining (Figure 2B, C, D; respectively) when compared to normal (Figure 2A).
When the CNS undergoes neurodegeneration, neurons bind silver causing
individual cells and processes to appear ‘blackened’ with this staining method.
Thus, at low magnification, diffuse silver staining was appreciable in the
cerebellum at 6 mo. of age, most notably in the white matter tracts throughout the
vermis and lateral hemispheres. As the mice aged, the intensity and distribution
of staining increased to include ‘patches’ throughout the Purkinje cell and
molecular cell layers.

At 8 mo. of age, widespread neurodegeneration was

evident in the anterior lobes of the cerebellum, although the staining was of equal
or lower intensity.
Higher magnification images of a 7 mo. old PPT1-/- brain show
parasagittal bands of degenerating Purkinje cells in the cerebellar cortex of the
vermis and lateral hemispheres (Figure 2E, F). The molecular layer was littered
with fragmented dendritic arbors associated with dying Purkinje cell neurons
(Figure 2H). In addition to their dendritic arbors, the cerebellar white matter
tracts, composed of afferant and efferent fibers, displayed an intense silver
staining (Figure 2G, I).
Purkinje cell degeneration
The Purkinje cell layer in wildtype mice consists of a one-cell-thick
monolayer of contiguous Purkinje neurons nestled between the molecular and
granular cell layers of the cerebellum (Figure 3B). In contrast, there was a clear
disruption in the Purkinje cell layer in PPT1-/- mice (Figure 3B), immediately
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Figure 3. Purkinje cell loss in the PPT1-/- cerebellum. (A) Schematic representation of
lobes I-X of the cerebellar vermis. (B) H&E stained cerebella from PPT1-/- and wildtype mice.
Black arrows indicate a contiguous Purkinje cell monolayer present in WT cerebellum. In the
PPT1-/- cerebellum, white arrows indicate patches of missing Purkinje neurons. (C) Graphical
representation of Purkinje cell survival (total cell number±SEM) in PPT1-/- cerebella at 1, 3, 5,
6, and 7 mo. of age. (D) Purkinje cell survival by lobe (as a percent of normal) in 1, 3, 5, 6, and
7 mo. PPT1-/- mice. (E) Calbindin staining in the PPT1-/- cerebellum. At low magnification,
there were comparable levels of staining in a 1 mo. WT and PPT1-/- cerebellum. By 3 mo. of
age, loss of calbindin staining appeared in patches throughout the anterior cerebellum (arrows).
By 7 mo. of age, nearly half of the cerebellum lacked calbindin immunoreactivity. At high
magnification, the molecular and Purkinje cell layers of 1 mo. WT and PPT1-/- cerebella
appeared normal with darkly stained Purkinje cell bodies and dendritic arbors. As the mice
age, there was a decrease in the intensity of calbindin staining, a denudation of the Purkinje
cell layer and pruning of the dendritic arbors. The white arrow identifies a swollen dendrite.
Comparable levels of calbindin staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice.
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illustrating cell loss at 7 mo. of age throughout both the anterior-posterior as well
as the medial-lateral axis of the cerebellum.

Additionally, remaining Purkinje

cells appeared unhealthy, presenting with a shrunken cytoplasm and a foamy
appearance characteristic of lysosomal distension. To further investigate this
apparent neuronal loss, Purkinje cell counts were performed throughout the
vermis on each lobe (I-X; Figure 3A) from wildtype and PPT1-/- brains at 1, 3, 5,
6, and 7 mo. of age. At 5 mo. of age, there was a trend towards a decrease in
total Purkinje cell number (13% decrease in total number; p=0.08). By 6 months
of age, there was a statistically significant decrease in total Purkinje cell number
(p=0.005) and culminated in a 50% reduction in total number at 7 mo. of age
(p<0.0005; Figure 3C). Regionally, loss of Purkinje cells began at 3 mo. of age in
the most anterior lobes. Although there was only a 3% decrease in total Purkinje
cell number at 3 mo., there was a 23% decrease in cell number in lobe I/II
compared to normal littermates (Figure 3D).

By 5 mo., Purkinje cell death

increased in posterior lobes. At 6 mo. of age, pairwise comparisons conducted
for each lobe showed significant cell loss (beyond Bonferroni correction) in lobes
I/II (p=0.039), IV/V (p=0.019), VI (p=0.001), VII (p=0.018), and VIII (p=0.003),
with lobes IX and X spared. All lobes suffer a ≥50% reduction in Purkinje cell
number by 7 mo. of age (p≤0.001).

No change in Purkinje cell number is

observed in PPT1-/- mice at 1 mo. of age.
In addition to quantifying neuronal loss, we investigated the morphology of
the remaining neurons as an indicator of their general health. To examine any
gross changes seen in Purkinje cell morphology, a time course of PPT1-/- and

28

wildtype control brains were stained with an antibody against the calcium binding
protein, calbindin. At low magnification, calbindin-stained Purkinje cells from lobe
IV/V appeared indistinguishable in PPT1-/- brains compared to age-matched
normal littermates at 1 mo. of age (Figure 3E). A contiguous layer of calbindinpositive cell bodies occupied the Purkinje cell layer, while the molecular layer
was filled with a network of darkly stained dendritic arbors (black arrows). In
addition, axonal projections from the Purkinje cell layer were observed
transversing the granular cell layer. At 3 mo., gaps in calbindin-positive staining
were appreciable at low magnification in the anterior lobes (I-V) of the PPT1-/cerebellum, consistent with our counts of Purkinje cell number.

At higher

magnification, there was a decrease in the density of staining within the
molecular layer demonstrating a pruning of dendritic arbors of the Purkinje cell
neurons. By 5 mo. of age, numerous disruptions in calbindin staining throughout
the anterior-posterior axis of the cerebellum were seen at low magnification. At
higher magnification, the molecular layer appeared disorganized while the axonal
projections through the granular cell layer looked fractured and swollen. By 7
mo. of age, Purkinje cell loss was widespread, with large gaps in staining
throughout the cerebellar vermis. In addition, frank cell loss was appreciable in
the lateral hemispheres of the cerebellum similar to the vermis (data not shown).
On closer inspection, the soma of Purkinje neurons often displayed irregular
margins with little to no dendritic arborization observed. Where arbors remained,
swollen dendrites in Purkinje cells were observed (Figure 3E; white arrow). In
addition to the profound Purkinje cell death that occurs in the PPT1-/-
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cerebellum, the remaining Purkinje cells, even at an early time point, appeared
unhealthy.
Apoptosis and Assessment of Granular Cell Loss
Although widespread Purkinje cell loss occurs at a variety of ages, the
only TUNEL-positive profiles were observed within the granular cell layer on
PPT1-/- mice at 7 mo. of age (Figure 4A). To investigate granule cell loss, cell

Figure 4. Cell loss in the granular cell layer. (A) TUNEL-positive cells were found in
the granular cell layer (GCL) of the 7 mo. PPT1-/- cerebellum. Nuclear fast red staining
identified cells within the granular cell layer at low magnification. At high magnification,
numerous darkly stained, TUNEL + profiles were observed throughout the GCL (dark
staining; arrows). (B) Quantification of the granular cell number demonstrated a
statistically significant (p<0.05; asterisk) cell loss at 7 mo. of age, with no changes in total
cell number evident before this age. No TUNEL positive cells were observed in 1, 3, 5, 6,
and 7 mo. wildtype mice.

counts in the granular cell layer were performed throughout the vermis of lobe
IV/V in wildtype and PPT1-/- brains at 1, 5 and 7 mo. (Figure 4). At 7 mo. of age,
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there was a statistically significant [F(1,4) = 44.37, p = 0.003] decrease in total
number of cells within the granular cell layer in PPT1-/- mice. Total cell number
was estimated to be 3.46x105 within lobe IV/V of mutant mice compared to
4.47x105 in age-matched wildtype controls (Figure 4B). This represents a 23%
percent cell loss in the granular cell layer at 7 mo. of age. At earlier time points
investigated, there was no decrease in the number of granule cells in lobe IV/V,
suggesting this loss of neurons is a later stage phenomenon.
Astrocyte activation
Astrocyte activation, visualized by glial fibrillary associated protein (GFAP)
upregulation, began at an early age (Figure 5A). At 1 mo. of age, there was a
slight increase in GFAP staining in PPT1-/- mice compared to wildtype controls.
By 3 mo., the Bergmann glia (Golgi epithelial cells) displayed a clear increase in
GFAP immunoreactivity both at the cell body and within their processes. At low
magnification, this staining appeared ‘patchy’ throughout the A-P axis of the
cerebellum. Astrocyte activation continued to increase at 5 mo. of age, and by 7
mo., the entire molecular layer throughout the vermis of lobes I-X was strongly
immunoreactive for GFAP.

At high magnification, there was an increase in

number of GFAP-stained Bergmann glial processes in the molecular layer as well
as an apparent hypertrophy of individual glial processes.
Astrocyte Dysfunction
In an effort to quantify astrocyte cell number, S100ß staining, a calcium
binding protein largely localized to astrocytes, was performed on cerebella from
PPT1-/- and wildtype littermates (Figure 5B). As the PPT1-/- mice aged, there
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Figure 5. Astrocyte changes in the PPT1-/- cerebellum. (A) GFAP staining was
performed on 1, 3, 5, and 7 mo. PPT1-/- cerebella. Astrocyte activation was found in PPT1-/mice as early as 1 mo. of age, with a diffuse increase in GFAP immunoreactivity. By 3 mo. of
age, there was a hypertrophy of astrocytic processes and patches of GFAP upregulation
through the PPT1-/- cerebellum (black arrows). This phenomenon continues as the mice age.
Comparable levels of GFAP staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice.
(B) Astrocyte dysfunction in the PPT-/- mouse. S100ß staining was performed on 1, 3, 5, 6,
and 7 mo. PPT1-/- cerebella. Compared to WT, there was an overall decrease in S100ß by 5
mo. of age (black arrows). Most notably, there was a progressive loss of immunoreactivity in
the Bergmann glia and astrocytes of the granular cell layer.
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was an overall decrease in S100ß staining throughout the cerebellum. In the
wild type control, S100ß-positive cell bodies were mostly localized within the
granular and Purkinje cell layers. Diffuse staining of Bergman glial fibers was
also apparent within the molecular layer. By 3 mo. of age, the PPT1-/- cerebella
showed a decrease in the intensity of S100ß immunoreactive cell bodies, most
notably within the granular cell layer.

As the mice age, the S100ß -positive

Bergman glia, with their cell bodies intermixed with Purkinje neurons in the
Purkinje cell layer, demonstrated a loss of immunoreactivity. In addition, there
was a diffuse loss of S100ß staining within all layers of the 7 mo. PPT1-/cerebellum. S100ß -positive cell bodies were absent from both the Purkinje cell
and granular cell layers.
Glutamine Synthetase (GS), GLAST, & GLT-1 Immunohistochemistry
To further investigate whether the loss of S100ß immunoreactivity was
due to changes in protein expression or due to a loss of astrocytes, we used a
second astrocyte marker, glutamine synthetase (GS), to stain 7 mo. old wildtype
and PPT1-/- mice (Figure 6). There was a decrease in GS staining in the 7 mo.
PPT-/- cerebellum compared to normal controls.

Although there was an

appreciable loss of neuropil in the PPT1-/- cerebellum at 7 mo., the remaining
cells in the granular cell layer stained for GS. Qualitatively, the number of GSpositive cell bodies in the molecular layer seemed less than the wild type control.
Importantly, there was a considerable decrease in the number of GSimmunoreactive cell bodies in the Purkinje cell layer, suggestive of a loss of
Bergman glia at 7 mo. of age.

33

Figure 6. Glutamine synthetase (GS), GLAST, and GLT-1 staining in 7 mos.
PPT1-/- and WT mice. An apparent loss of GS staining was observed in the
cerebellar cortex of 7 mos. PPT1-/- mice. Most notably, there was a loss of staining
within the cell bodies of the Bergmann glia (black arrows). GLAST staining in PPT1-/mice demonstrated a diffuse, overall reduction in immunoreactivity compared to WT.
A decrease in GLAST expression in the Bergmann glia (arrows) and the molecular
layer was also apparent. In contrast, GLT-1 staining was comparable in WT and
PPT1-/- mice. A notable exception is the intensity of staining in the Purkinje cell
layer, which was markedly reduced in the PPT1-/- mice.

34

Given the number of changes observed in PPT1-/- astrocytes, we
performed

immunohistochemistry

staining

for

several

astrocyte

specific

glutamate transporters, GLAST and GLT-1, in PPT1-/- and wild type mice (Figure
6). At low magnification, the wild type-Bergman glia were largely immunoreactive
for GLAST, with punctate staining present in the Purkinje cell and molecular
layers. In contrast, the PPT1-/- cerebellum at 7 mo. of age suffered an overall
decrease in GLAST immunoreactivity. At higher magnification, this change in
protein expression was most notable in the Bergmann glial processes in the
molecular layer, with a near complete loss of staining at 7 mo. of age.
Although GLAST expression was altered in the PPT1-/- mice, GLT-1
staining in the cerebellar folia seemed relatively unchanged when compared to
wildtype littermates.

The major change in GLT-1 staining in mutant mice

coincided with a loss of Purkinje cells at 7 mo. of age. The normal pattern of
GLT-1 staining circumscribes the Purkinje cell bodies and in their absence in
mutant mice, this staining is lost. Otherwise, comparable patterns and levels of
GLT-1 staining were apparent in both PPT1-/- and wildtype cerebella in the
granular cell and molecular layers.
Microglial Reactivity
PPT1-/- and wildtype brains were stained for F4/80, a marker for microglia
and macrophages (Figure 7). Prior to 5 mo. of age, there was no detectable
F4/80 staining within the brains PPT1-/- mice or wildtype littermates. At 5 mo. of
age, an increase in F4/80 staining was evident in the PPT1-/- cerebellum. The
F4/80-positive cells, mostly comprised of small-ramified cells, were evenly
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dispersed throughout the molecular, Purkinje cell, and granular cell layers. As
the mice age, there was a progressive increase in the number of positively

Figure 7. F4/80 staining, a monocyte marker, in PPT1-/- and wildtype mice. PPT1-/- mice
showed an increase in the number of monocytes starting at 5 mos. of age. As the mice age,
there was an increase in monocytes at 6 and 7 mos. (black arrows). In addition, there was a
change in the morphology of the F4/80 positive cells from small, ramified cells with a microglial
morphology (A) to larger rounded brain macrophage-like cells (B). Comparable levels of F4/80
staining were observed in 1, 3, 5, 6, and 7 mo. wildtype mice.

stained cells in the PPT1-/- cerebellum.

In addition, the morphology of the

positive cells changed from small-ramified cells (A) to large, round cells with
brain macrophage-like morphology (B) as the mice age.
Luxol Fast Blue and Periodic acid Schiff staining
Luxol Fast Blue (LFB) and Periodic acid Schiff (PAS) staining were
performed on 7 mo. old PPT1-/- mice and normal littermates (Figure 8). Upon
gross examination, the white matter tracts, as visualized by LFB, appeared
thinner in PPT1-/- mice (arrows) compared to normal littermates.

At higher

magnification, LFB staining revealed an array of densely stained myelinated
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fibers traversing through the white matter in the wildtype mouse. In contrast, the
PPT1-/- cerebellar white matter appeared disorganized, less intensely stained

Figure 8. Luxol Fast Blue (LFB) and Periodic acid-Schiff (PAS) staining in
the PPT1-/- cerebellum. Staining for the myelin marker, luxol fast blue, was
markedly decreased in PPT1-/- mice at 7 mo. At low magnification, there was a
thinning of the cerebellar white matter tracts in the PPT1-/- mice compared to
WT. At high magnification, the intensity of staining and organization of the
white matter was disrupted in the PPT1-/- cerebellum. PAS staining (red)
demonstrated glycogen inclusions in the molecular layer and Purkinje cell layers
of PPT1-/- mice. In addition, the vasculature in the white matter tracts was PAS
positive (arrows).

and littered with ‘holes’. Furthermore, the number of densely stained cell bodies
in the white matter was decreased and the morphology of the remaining cell
bodies appeared shrunken and irregular in PPT1-/- mice. These densely stained
cells are glia, most likely oligodendrocytes, given their localization and
organization in the cerebellar white matter.
PAS staining, a marker of glycogen storage was performed on 7 mo.
PPT1-/- mice. There was a noticeable increase in the intensity of PAS staining in
the vasculature of the white matter tracts (black arrows).
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In addition, PAS-

positive cells were present in the molecular layer and Purkinje cell layers of the
PPT1-/- cerebellum, but only at a late stage of disease (5-7 mo.).
Rotarod Testing
PPT1-/- mice and normal littermates were tested on the rotorod at 1, 3, 5,
6 and 7 mo. of age and latency to fall was recorded (Figure 9). At 1 mo. of age,
the performance of PPT1-/- mice and normal littermates was indistinguishable on
the rotorod (54.9s v. 54.7s; respectively). The latency to fall began to decrease

Figure 9. Constant speed rotarod testing in the PPT1-/- mice. PPT1-/mice display significant motor deficits (p<.0.0005) on the rotarod test
beginning at 5 mo. of age, and continuing through 6 (p<.0.0005) and 7
(p≤0.001) months of age. The asterisk denotes statistical significance. WT
mice performed at criterion for the entire task.

in PPT1-/- mice compared to WT mice at 3 mo. of age (55.6s v. 48.9s;
respectively), although this was not a significant change. By 5 mo. of age, the
ability of the PPT1-/- mice to stay on the rotorad was significantly impaired
(39.5s; p≤0.0005), while wildtype littermates continued to perform near criterion
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(55.9s).

The performance of PPT1-/- mice continued to decrease at 6 mo.

(27.1s; p<0.0005) and reached a nadir at 7 mo. of age (1.8s; p≤0.001).
Repeated measures ANOVA revealed a significant main effect of group, [F(1,26)
= 68.75, p < 0.0005], a significant effect of age, [F(2,52) = 24.16, p < 0.0005],
and a significant group by age interaction, [F(2,52) = 27.84, p < 0.0005].

Results from Forebrain Study
Astrocyte activation is an early stage phenomenon
Astrocyte activation, as identified by GFAP upregulation, is one of the first
pathological changes observed in the PPT1-/- brains (Figure 10). The forebrains

Figure 10. Early astrocyte activation precedes neuronal loss. GFAP staining in 1, 3, 5,
and 7-month-old PPT1-/- and 7-month-old WT brains. Focal areas of GFAP upregulation
occur in the PPT1-/- brain beginning at 1-3 months of age. Specifically, there is a notable
increase in GFAP staining in the cortex, thalamus, and cerebellum of PPT1-/- mice. The
intensity and distribution of GFAP increases as the PPT1-/- mice age.

from PPT1-/- and WT mice at 1, 3, 5, and 7 mos. of age were stained with GFAP.
By 3 mos. of age, a statistically significant increase in GFAP staining was present
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in the PPT1-/- forebrain, most notably within the cortex and thalamus (Figure
11A). Initially, diffuse staining was present across all cortical laminae, in multiple
regions of the cortex (i.e. motor, somatosensory, visual). As the mice aged, the
intensity and distribution of GFAP staining increased. In contrast to the cortex,
GFAP staining in the thalamus was more localized to individual thalamic nuclei.
By 3 mos. of age, the lateral geniculate (LGN), medial geniculate (MGN), ventral
posterior (VPM/VPL), mediodorsal (MD), central medial (CM), and reticular
thalamic (Rt) nuclei were all densely stained. As the mice aged, GFAP staining
increased in intensity but also spread to include adjacent thalamic regions. By 7
mos. of age, the entire forebrain in the PPT1-/- mouse contained astrocyte
activation.
Neuronal loss in the thalamus
In the PPT1-/- forebrain, the thalamus is one of the first areas to undergo
neuronal loss.

Neuronal loss in the thalamus is progressive in nature and

specific to individual nuclei.

The LGN, part of the visual center, is the first

nucleus to degenerate at 3 mos of age. Neuronal loss in the remainder of the
thalamic nuclei, including the MGN, VPM/VPL, and Rt, did not begin until 5 mos.
of age. Thus, these data indicate that neuronal loss in the thalamus is a later
stage phenomenon beginning at 5 mos. of age.
Cortical atrophy and neuronal loss
Although cortical thinning is one of the key elements of disease in INCL,
this pathological change is a later stage phenomenon. A statistically significant
decrease in cortical thickness is not present until 5-7 months of age (summarized
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in Figure 11B).

Also, cortical atrophy is not uniform but varies depending upon

the region assayed. For example, cortical thinning was present in the motor,

A

C

B

Figure 11. Summary of Forebrain Pathology in the PPT1-/- mouse. (A) Threshold analysis
of GFAP stained images in the S1BF cortex demonstrates a quantitative increase in staining as
the PPT1-/- mice age. By 3 mos. of age, this is a significant increase when compared to WT
brains. (B) A summary of the time course of significant neuronal loss (p<0.05 level) in the
forebrain. Neuronal loss is first observed in the thalamus, with neuronal death occurring in
cortical relays later. (C) F480 threshold analysis demonstrates that microglia activation is a late
stage phenomenon in the S1BF cortex. A significant increase in F480 staining begins at 5 mos.
in the PPT1-/- mice but steadily increases as the mice age.

visual, and auditory cortex, where no statistically significant change in cortical
thickness was found in the somatosensory or entorhinal cortex. Furthermore, the
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visual cortex is the first region to demonstrate atrophy at 5 mos. of age, while the
motor and auditory cortex do not degenerate until 7 mos. of age.
Quantitation of neuronal number reinforced the finding that cortical
degeneration is a late stage phenomenon. Neuronal loss is first seen in the
visual cortex at 5 mos. of age.

However, neuronal loss occurs in the

somatosensory cortex at 7 mos. of age. These data demonstrate that cortical
atrophy and neuronal loss occur subsequent to neuronal loss in their thalamic
relays.
Microglial reactivity is a late stage phenomenon
While astrocyte activation is an early stage phenomenon, microglial
activation occurs during the later stage of disease (Figure 11C).

Microglial

reactivity, as visualized by F4/80 staining, was not significantly elevated until 5
mos. of age. Prior to that time, little or no reactive microglia were present in the
brain

suggesting

neurodegeneration.

that

microglia

reactivity

occurs

in

response

to

Furthermore, the number of activated microglia increased

in both the thalamus and cortex as the mice age.
Seizure Activity
PPT-/- and WT mice at 6, 6.5, 7 and 7.5 mos. of age were monitored by
EEG recordings and video surveillance for spontaneous seizure activity (Figure
11). No seizure activity was present in PPT1-/- mice prior to 7 mos. of age. At 7
mos. of age, only 50% of all PPT1-/- mice had seizures while 100% of 7.5 mos.
old mice had seizures. There was no change in seizure duration or frequency in
the 7 or 7.5 mos. old mice. The interictal EEG tracings were scored for all
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Figure 12. Progressive development of the seizure phenotype in PPT1-/-mice. (A)
Representative example of a seizure recorded in a PPt1−/− mouse by two channel EEG.
(B) Seizures were not evident in PPT1−/− mice until 7 months of age and were present in
all mutant mice by 7.5 months of age, but were not present in age-matched controls (+/+).
There was no significant difference between mutant mice in the frequency or duration of
seizures at 7 and 7.5 months of age. Graded scoring of EEG recording traces also
revealed a significant worsening of the interictal background EEG in mutant mice above 7
months of age, compared to mutant mice at 6 and 6.5 months of age and age-matched
controls (***p < 0.001, ANOVA with post hoc Tukey–Kramer multiple comparisons).
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animals tested.

There were no significant differences in the interictal EEG

tracings of 6 and 6.5 months PPT1-/- mice when compared to WT.

However,

with the onset of seizure activity, the background EEG patterns were abnormal
by 7-7.5 mos. of age.

Discussion
Although pathological changes within the PPT1-/- forebrain at an end
stage of disease were described in detail (Bible et al., 2004; Griffey et al., 2004),
little is known about the morphological and functional changes localized to the
hindbrain. Since reports of INCL patients describe profound cerebellar pathology
(Haltia et al., 1973a; Haltia et al., 1973b) and motor deficits (Santavuori et al.,
1974), a complete characterization of the disease progression within the PPT1-/cerebellum is essential.

Our findings demonstrate that substantial pathology

exists within the PPT1-/- cerebellum, consistent with the human course of
disease. At an end stage of disease, there was significant cerebellar atrophy,
suggesting profound cell loss in the PPT1-/- cerebella.

We performed silver

degeneration staining to investigate which aspects of the cerebellum were most
affected. Staining of the cerebellar white matter was first observed, suggesting
the major afferent and efferent projections were undergoing widespread
degeneration.

Similarly, the molecular and Purkinje cell (PC) layers were

argyrophillic, identifying ‘patches’ of degenerating PC bodies and dendritic
arbors. As described by Sarna and Hawkes (2003), PCs in the cerebellum are
highly organized into parasagittal bands (based on zebrin II immunoreactivity),
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which carry their own molecular fingerprint, and are differentially susceptible to
toxic insults. Silver staining suggests that specific classes of PPT1-/- PCs are
more susceptible to cell death than others.
Quantification of the PC layer showed a trend towards early neuronal loss.
As described above, the death of PCs throughout each lobe was not random but
rather a stereotyped wave of cell death beginning in the anterior lobes of the
cerebellar vermis and later affecting the posterior lobes. Although an increased
sensitivity of certain classes of Purkinje cells is described in cerebellar mutants,
lysosomal storage diseases (LSDs) with a cerebellar involvement preferentially
affect the anterior lobes. Other LSDs such as Nieman Pick Type A/B (Macauley
et al., 2008a; Macauley et al., 2008b; Sarna et al., 2001), Nieman Pick Type C
(Sarna and Hawkes, 2003), and late infantile neuronal ceroid lipofuscinosis
(Chang et al., 2008; Sleat et al., 2004) detail a vulnerability of the PCs in the
anterior lobes to cell death.

Some have postulated that increased levels of

metabolic enzymes (Slemmer et al., 2007), increased glutamate transporter
expression (EAAT4) (Welsh et al., 2002) and the presence of small heat shock
proteins (Armstrong et al., 2000, 2001) is thought to be neuroprotective for PCs
in the posterior lobes.
Although some PCs are initially more resistant to toxic insults in INCL, the
posterior lobes still become affected later in disease progression.

This

phenomenon is consistent with other LSDs, but dissimilar to other cerebellar
mutants (reviewed in (Sarna and Hawkes, 2003).

Even if a subset of PCs

survives longer than others, we hypothesize that their function is compromised
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based on the morphological changes observed (Figure 3).

Electrophysiology

experiments are needed to evaluate surviving PCs.
Consistent with PC loss in the PPT1-/- cerebellum, there was an age
dependent decline in rotarod performance. As PCs begin to die at 3 mo. of age,
there is a concurrent decrease, although not significant, in PPT1-/- performance
on the rotarod, which worsens with age.

Significant performance deficits

(p≤0.05) on the constant speed rotarod are seen at 5 mos. of age, which
coincides with a trend towards Purkinje cell loss that becomes significant by 6
mos. of age. These data demonstrate a strong relationship between cerebellar
pathology and motor function, a phenomenon seen in other LSDs (Macauley et
al., 2008). Furthermore, these findings correlate with the loss of neurons within
motor pathways in the basal ganglia and thalamus (Kielar and Cooper,
unpublished observations), which may also contribute to this phenotype.
In contrast to PC loss, apoptotic cell death in the granular cell layer is a
later stage phenomenon.

These data illustrate a selective vulnerability of

cerebellar neurons to cell death, an important consideration for therapeutic
delivery and timing.
Recent reports on the NCLs (Bible et al., 2004; Chang et al., 2008; Kielar
et al., 2007; Pontikis et al., 2005) demonstrate that gliosis occurs early in disease
pathogenesis (reviewed in (Cooper et al., 2006).

Similarly, activation of the

PPT1-/- Bergmann glia was the first cerebellar change. Gliosis is a common
component of many neurodegenerative disorders, yet it remains unclear whether
this process is helpful or harmful to a chronically diseased CNS.
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GFAP

upregulation is used as a marker of gliosis, yet its exact role in CNS disease
remains uncertain. We hypothesize that an early stage gliosis occurs for several
reasons. First, astrocyte activation is occurring in response to altered neuronalglial interactions (see below). In response to neuronal or glial stress, astrocytes
shift roles from a quiescent to a reactive astrocyte early in INCL.

We

hypothesize this shift stabilizes glutamatergic synapses to maintain the health of
the CNS.

Thus, we hypothesize that activated Bergman glia are modulating

neuronal-glial interactions in an effort to prevent CNS damage. Secondly, we
hypothesize that early stage astrocyte activation occurs as an anti-inflammatory
mechanism within the CNS and at the gliovascular unit. We postulate reactive
astrocytes restrict access of systemic immune cells to the CNS via modulation of
the blood brain barrier and/or chemokine signaling.
Although INCL is described as a neurodegenerative disorder, there is
prominent astrocyte pathology in the PPT1-/- cerebellum, a phenomenon likely
independent of astrocyte activation. As previously reported, normal astrocytes
express PPT1 (Haltia, 2003; Margraf et al., 1999), and PPT1-deficient astrocytes
accumulate GRODs (Galvin et al., 2007). Our studies demonstrate a decrease in
S100ß staining at early stages in PPT1-/- mice, most notably in the Bergman
glia, suggesting a primary pathology in astrocytes. Interestingly, S100ß staining
is typically upregulated, not down regulated in CNS injury (i.e. neurodegenerative
disorders, traumatic brain injury, etc.), (Goncalves et al., 2008; Griffin et al.,
1995; Mrak and Griffinbc, 2001; Rothermundt et al., 2003; Wainwright et al.,
2004). This reduction of S100ß in astrocytes could be due to the secretion of
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S100ß into the extracellular space, a neurotoxic event in the adult brain
(reviewed in Donato, 2003).

Alternatively, the loss of S100ß staining may

represent astrocytic cell loss. To investigate this, we stained PPT1-/- cerebella
for glutamine synthetase, an astrocyte specific enzyme important for glutamateglutamine recycling. GS staining in the Bergman glia was decreased or largely
absent in the PPT1-/- cerebellum, suggesting that astrocyte dysfunction or cell
loss is a prominent feature in disease pathogenesis.
GLAST staining further illustrated pathological changes in astrocytes.
GLAST, an astrocyte specific glutamate transporter, is responsible for glutamate
clearance at the synaptic cleft. An overall decrease in GLAST expression was
observed in the aged PPT1-/- cerebellum. Furthermore, specific loss of GLAST
is observed in the Bergman glia circumscribing PCs. Although comparable levels
of GLT-1 were observed in the PPT1-/- cerebellum, GLAST is the main
glutamate transporter in Bergman glia, thus demonstrating a potential disruption
in glutamate recycling in the PPT1-/- cerebellum. Furthermore, localized changes
in the expression of glutamate and both astrocytic and neuronal glutamate
transporters are also evident in the thalamus, basal ganglia and hippocampus
(Kielar and Cooper, unpublished observations), suggesting that altered
glutamate/glutamine cycling may be an important feature of INCL pathogenesis.
Although changes in astrocytes and neurons occur at an early stage in
INCL, changes in microglia and oligodendrocytes occur later. As the mice age,
there is an increase in F4/80+ cells in the CNS as well as changes in their
morphology (Figure 7A,B). We hypothesize that microglial activation is initially
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mounted in the PPT1-/- cerebellum to clear cellular debris. As the mice age,
there is a secondary macrophage infiltration in INCL where circulating immune
cells invade the PPT1-/- CNS. It will be important to determine the relationship
between these events, neuron loss, and blood brain barrier permeability.
Demyelination is seen in the aged PPT1-/- cerebellum.

At autopsy,

patients with INCL suffer a near complete loss of myelin in the CNS (Haltia,
2003). Not surprisingly, we found atrophy of the cerebellar white matter tracts as
well as a loss of myelin components, such as CNPase (data not shown), in the
PPT1-/- cerebellum. Whether this demyelination is due to the axonal death of
PCs or a primary oligodendrocyte dysfunction needs further investigation.
The temporal-spatial characterization of the cerebellum successfully
identified a time line for cellular pathology in the PPT1-/- brain (Figure 12). The
first pathological change observed in the PPT1-/- cerebellum is astrocyte
activation at 1-3 months of age. This change preceded neuronal loss, in either
the Purkinje cell or granular cell layers.

By 5-7 mos. of age, there was a

significant neuronal loss throughout the cerebellum concurrent with other
changes in the glial population. Specifically, by 7 mos. of age, there appears to
be loss of the Bergmann glia, frank demyelination in the cerebellar white matter,
and late stage microglial reactivity. Interestingly, the motor deficits observed in
the PPT1-/- mouse correlated with neuronal loss as a mid to late stage event.
A similar time line occurred regarding studies performed on the PPT1-/forebrain (Figure 13).

Similar to the cerebellum, the first pathologic change

observed was astrocyte activation in both the cortex and thalamus of PPT1-/-
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Figure 13. Summary of disease progression in the PPT1-/- mouse. Disease progression is
broken down into 3 stages- early (1-3 mos.), mid (3-5 mos.), and late (5-7 mos.). During the
early phase of disease, the first pathological change observed is astrocyte activation, delineated
by GFAP upregulation. Neuronal loss within the thalamus begins during the mid stage of
disease, with neuronal loss in the cortex to follow. Finally, at an end stage of disease, there is
microglial activation and functional deficits in the PPT1-/- mice.

mice at 3 mos. of age.

Subsequently, there was localized neuronal loss in

thalamic nuclei were astrocyte activation had occurred. Following neuronal loss
in the thalamus, cortical atrophy and neuronal loss occurred in the PPT1-/- brains
at 5-7 mos. of age. Neurodegeneration correlated with an increase in microglia
reactivity in both the cortex and thalamus. The onset of seizure activity and
changes in the interictal EEG pattern occurred at 7 mos. of age, coinciding with
neuronal loss in cortex and thalamus.
These studies provide a comprehensive characterization of cellular
pathology and its relationship to behavioral dysfunction in INCL.

We

demonstrate that cellular pathology is not restricted to neurons, and that a
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concurrent glial involvement, most notably in astrocytes, exists. We demonstrate
that astrocyte activation is one of the first pathological changes observed in
either the forebrain or hindbrain of PPT1-/- mice. With a better understanding of
how the disease progresses in INCL, we can identify possible avenues for
intervention in future therapy studies. Since clinical trials for LINCL and INCL are
ongoing (Sondhi et al., 2008; Sondhi et al., 2005; Taupin, 2006; Worgall et al.,
2008; Zhang et al., 2001), our studies identify the need to target therapies not
only to the forebrain of patients suffering from INCL, but also to the hindbrain. It
also provides evidence of profound glial involvement and thus necessitates the
development of therapies aimed at treating both neuronal and glial dysfunctions.
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Chapter Three

The role of astrocyte activation,
as defined by GFAP upregulation,
in a mouse model of INCL
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Introduction
Characterization studies in the PPT1-/- mice yielded valuable insights into
the progression of CNS disease in INCL (Kielar et al., 2007; Macauley et al.,
2009).

Previous studies demonstrated that localized areas of astrocyte

activation, as defined by an increase in glial fibrillary acidic protein (GFAP)
expression, are the first pathological changes observed in the PPT1-/- brains. By
1-3 months of age, there is a significant increase in GFAP staining in the
thalamus, cortex, and cerebellum. Interestingly, the thalamus, cortex, and
cerebellum also suffer the greatest neuronal loss and regional atrophy
subsequent to this early astrocyte activation. Thus, we hypothesize that astrocyte
activation, in particular GFAP upregulation, plays an active role in the
pathogenesis of INCL, given its temporal-spatial association with future sites of
neurodegeneration. By investigating the role of astrocyte activation and GFAP
upregulation, we will determine whether gliosis is protective or harmful to the
underlying neurodegeneration and functional deficits associated with INCL.
GFAP Upregulation and Astrocyte Activation
Astrocyte activation, or reactive gliosis, although often described, is a
poorly understood phenomenon in CNS injury and disease (Kalman, 2004;
Pekny and Nilsson, 2005; Sofroniew, 2005). Although GFAP upregulation is the
classic biomarker of gliosis, the relationship between increased GFAP
expression and functional changes remains unclear. This ambiguity is partly
because the role of GFAP as a key intermediate filament protein in astrocytes
remains poorly understood (Messing and Brenner, 2003; Pekny, 2001).
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As

important components of astroglial cells, intermediate filament proteins, such as
GFAP, vimentin and nestin, are thought to regulate the shape, structure, and
motility of astrocytes (Eng et al., 2000; Potokar et al., 2007). More specifically,
GFAP is also responsible for stabilizing astrocytic processes, organizing
organelles within cytoplasm, as well as anchoring glutamate transporters (i.e.
GLAST) to the plasma membrane (Sullivan et al., 2007). Studies from GFAP-null
mice infer that the GFAP protein is involved in the maintenance of the blood brain
barrier, myelin, and neuronal synapses. Beyond these generalized or inferred
functions, the biological role of GFAP remains elusive. Moreover, the role of
GFAP in astrocyte activation, specifically, is unclear.
Although the function of GFAP is poorly understood, the correlation
between GFAP upregulation and astrocyte activation is clear and well described
(Bates et al., 2002; Hafiz and Brown, 2000; Haltia, 2003; Kobayashi et al., 2002;
Levine and Hoenig, 1972; Li et al., 2008; Murphy et al., 1992; Murray et al., 2006;
Oberheim et al., 2008; Pekny and Nilsson, 2005; Renkawek et al., 1999; Vajda,
2002). When the CNS is subjected to an insult or injury, there is an increase in
GFAP expression, which coincides with a shift from a quiescent astrocyte to an
activated astrocyte. In a healthy CNS, quiescent astrocytes are responsible for a
variety of functions, beyond providing structural integrity to the brain.

Most

notably, astrocytes maintain neuronal synapses via metabolic support,
neurotransmitter uptake, and glutamate recycling (Mazzanti et al., 2001;
Nedergaard et al., 2003; Perea et al., 2009; Ransom et al., 2003; Schousboe et
al., 1997; Volterra and Meldolesi, 2005; Walz, 2000). Astrocytes also form the
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gliovascular unit and modulate the blood brain barrier (BBB)(Goldstein, 1987;
Nedergaard et al., 2003).

In addition to neuron-glial and gliovascular

interactions, astrocytes are joined via gap junctions to create an astrocyte
syncytium responsible for the propagation of intracellular signals (Kielian and
Esen, 2004). In response to injury, quiescent astrocytes become “activated” or
“reactive” and adopt a secondary set of functions (Aschner, 1998a, b;
Daginakatte et al., 2008; Eddleston and Mucke, 1993; Heales et al., 2004;
Maragakis and Rothstein, 2006). Morphologically, reactive astrocytes upregulate
intermediate filament proteins like GFAP, vimentin (vim), and nestin resulting in
astrocyte hypertrophy (Pekny, 2001; Pekny and Nilsson, 2005). Both the number
and thickness of astrocytic processes increases giving these cells their star
shaped, or more accurately, “bushy” appearance (Wilhelmsson et al., 2006).
Beyond structural modifications, reactive astrocytes are transformed functionally;
they clear cellular debris, form glial scars, express cytokines, and promote
inflammation.
Although the process of gliosis is well described, it is often debated
whether these structural and functional changes in astrocytes are helpful or
harmful to the injured CNS. Reactive gliosis has largely been studied in models
of acute trauma or injury (Pekny and Pekna, 2004; Sofroniew, 2009; Sofroniew et
al., 1999).

Findings from these studies demonstrate that although reactive

astrocytes form glial scars that contain a site of injury, these cells also limit
regeneration of the CNS via both a physical (i.e. glial scar) and molecular (i.e.
cytokines) barrier (Daginakatte et al., 2008; Ridet et al., 1997; Voskuhl et al.,
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2009). Given the dichotomous nature of reactive astrocytes in acute injury, there
is an inherent need to gain a better understanding of this phenomenon,
specifically in chronic, neurodegenerative diseases.
The GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mouse
Recently, a mouse model lacking the intermediate filament proteins (IFs),
GFAP and vimentin, was created and can be utilized to address the relationship
between structural alterations (i.e. GFAP upregulation) and functional changes
(i.e. cytokine production, neurodegeneration, etc.) associated with astrocyte
activation in CNS injury and disease (Pekny et al., 1999).

When left

unchallenged, the GFAP-/-, Vim-/- double knockout (2KO) mice breed, develop
normally and live a normal lifespan. However, when the 2KO mice are exposed
to CNS injury, the outcomes are rather complex. In the case of mechanical
stress (i.e. traumatic brain injury, retinal detachment, stroke, etc.), the 2KO mice
showed a decreased structural stability in the absence of IFs resulting in more
damage (Kinouchi et al., 2003; Lane and Pekny, 2004; Li et al., 2008; Lundkvist
et al., 2004; Nakazawa et al., 2007; Pekny, 2001; Pekny and Pekna, 2004;
Verardo et al., 2008). Although the glial scar was less organized in these models
of CNS trauma resulting in larger infarct volumes, several of these models report
positive outcomes such as greater axonal sprouting, synaptic regeneration and
faster wound healing. In a model of retinal detachment, the 2KO demonstrated a
reduction in monocyte infiltration, cytokine expression, and photoreceptor cell
death. Taken together, results from studies using 2KO mice help elucidate both
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the positive and negative outcomes associate with reactive gliosis in models of
CNS injury.
Goals of Chapter 3
To further our understanding of the role of astrocyte activation in INCL, we
crossed the 2KO mouse to the PPT1-/- mouse, thus creating the GFAP-/-,
Vimentin-/-, PPT1-/- triple knockout (3KO) mouse. By knocking out GFAP and
Vimentin, we hypothesized we would alter how astrocytes react to injury in a
model of INCL. In this study, we investigated the effects of altered gliosis in the
PPT1-/- brain. We determined that astrocyte activation plays a protective role in
INCL and in its absence disease pathogenesis is accelerated. In the 3KO brains,
the hallmark characteristics associated with INCL, such as premature death,
brain atrophy, cortical thinning, and neurodegeneration, are exacerbated
compared to the PPT1-/- mice and controls.

Furthermore, the underlying

mechanisms responsible for this accelerated phenotype include immune cell
infiltration, cytokine upregulation, and a compromised gliovascular unit. Taken
together, the 3KO mouse provides valuable information concerning the role of
astrocyte activation in INCL.

Methods
GFAP-/-, Vimentin-/-, PPT1-/- Mice
The GFAP-/-, Vimentin (Vim) -/- double knockout (2KO) and PPT1-/- mice
were created through standard genetic techniques as previously reported. The
GFAP-/-, Vim-/- mice (a kind gift from Milos Pekny, University of Goteborg,
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Goteborg, Sweden) were crossed to the PPT1-/- mice (Griffey et al., 2005; Gupta
et al., 2001) to create the GFAP-/-, Vim-/-, PPT1-/-, or triple knockout (3KO),
mice. For the purposes of these studies, 3KO, 2KO, PPT1-/-, and wildtype (WT)
mice were generated and maintained at Washington University School of
Medicine as an outbred colony. Mouse genotypes were determined by PCRbased assays. Both male and female mice from each genotype were used in this
study.

Animals were housed under a 12:12 hour light:dark cycle and were

provided food and water ad libitum. All procedures were carried out under an
approved IACUC protocol from Washington University School of Medicine.
Brain Weights
Six-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=5-6 mice per
genotype per age) were sacrificed via a lethal injection of euthasol and the brains
harvested by a researcher blinded to both genotype and age. A razor blade was
inserted coronally between the forebrain and olfactory bulbs to remove the
olfactory bulbs from the remainder of the brain. Similarly, a coronal cut was
made immediately posterior to the cerebellum, separating it from the medulla and
spinal cord. Care was taken to ensure that the cuts were flush with the front of
the cerebrum and back of the cerebellum. Each brain was weighed using an
analytical balance. Group differences in weights were analyzed using a repeated
measure ANOVA with one between subjects’ variable (genotype), one withinsubjects variable (age), and subsequent pairwise comparisons.

Bonferroni

correction was used to maintain alpha levels at 0.05 when multiple comparisons
were conducted.
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Autofluorescent Accumulation
Six-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=3 mice per group)
were used to quantify autofluorescent accumulation in the somatosensory barrel
field (S1BF) cortex using epifluorescent microscopy (Bible et al., 2004; Kielar et
al., 2007).

Briefly, mice were given a lethal injection of euthasol, the brains

removed, and fixed for 48 hrs in 4% PFA in phosphate buffer. Following fixation,
the brains were cryoprotected in 30% sucrose, embedded in OCT, and sectioned
coronally on a freezing cryostat at 20µm thickness.

Images from 3 serial

sections through S1BF for each group were captured via a 20x objective and
FITC filter on a Nikon microscope with a SPOT camera attached. All variables
associated with image capture, including exposure time, binning, and gain, were
held constant for all groups.

Using ImageJ software, threshold analysis was

performed to determine which pixels contained autofluorescent accumulation in a
given image. The percentage of pixels containing autofluorescent material was
calculated for each image and reported as the area fraction. Three sets of area
fraction measurements were captured for each of the 3 sections through S1BF in
each of the 4 groups. The average for each group was calculated. Statistical
significance was assessed using an ANOVA followed by Bonferrini correction
post-hoc test.
Nissl Staining
Nissl staining was performed on six-month-old 3KO, 2KO, PPT1-/-, and
WT mice (n=3 mice per group). Briefly, mice were given a lethal injection of
euthasol, the brains removed, and fixed for 48 hrs in 4% PFA in phosphate
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buffer.

Following fixation, the brains were cryoprotected in 30% sucrose,

embedded in OCT, and sectioned coronally on a freezing cryostat at 20µm
thickness. Sections throughout the primary visual (V1) cortex were mounted on
glass slides, placed on a warming plate for 1 hr. and allowed to thoroughly dry
overnight at room temperature. Sections were briefly rinsed in dH20, incubated
in 0.5% cresyl violet for 2 mins., and rinsed with dH20. The sections were then
dehydrated via a series of alcohols and xylenes and coverslipped.
Cortical Thickness
Cortical thickness measurements were performed on Nissl stained tissue
from 3KO, 2KO, PPT1-/- and WT brains (n=3 brains per group).

Images

throughout V1 were captured at 10X magnification using an Olympus BX41
microscope and Olympuis DP 20 camera.

Cortical thickness measurements

were made from the boundary of the white matter to the pial surface for each
brain, as delineated by Paxinos and Franklin and as previously described(Bible
et al., 2004; Kielar et al., 2007). A series of 10 individual measurements were
made for each of 3 sections for each mouse (n=3 mice per group).

The mean

cortical thickness measurement for each mouse was determined. Statistical
significance was assessed using an ANOVA followed by Bonferrini correction
post-hoc test.
DeOlmos Cupric Silver Staining
5-month-old 3KO, 2KO, PPT1-/-, and WT mice (n=2 per time point) as well
as a time course of 3KO mice at 3, 5, and 6 mos. of age (n=2-3 per time point)
were processed for deOlmos silver staining.
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Briefly, the mice were deeply

anesthetized

with

euthasol

and

transcardially

perfused

with

4%

paraformaldehyde in sodium cacodylate buffer. The brains were removed and
post-fixed for 48 hours. Each brain was embedded in a gelatin-based matrix
(Switzer, 2000) and serial coronal sections (35 µm) were cut on a freezing
microtome by Neuroscience Associates (Knoxville, TN). Neuronal degeneration
was visualized by staining with a modified cupric silver method of DeOlmos
(DeOlmos & Ingram, 1972; Switzer, 2000). A matrix of PPT1-/- and WT brains at
identical levels in the coronal plane were stained simultaneously. Every sixth
section (210 µm interval) was stained with the silver method and adjacent
sections stained with H&E.
Blood Brain Barrier Permeability
Blood brain barrier (BBB) permeability was assessed in 7 mos. PPT1-/-,
7 mos. WT, and 5.5 mos. 3KO (n=4 mice per group) using an Evan’s blue assay
(Belayev et al., 1996; Young et al., 2004).

PPT1-deficient mice receiving a

middle cerebral artery occlusion (MCAO), or stroke, served as a positive control.
Mice were injected with 2% Evan’s blue in saline via a tail vein injection (4µl/ g of
body weight). After 30 minutes, the mice were transcardially perfused with PBS
until both the perfusate and liver were clear (approximately 1-2 minutes). The
brains were removed, bisected, and weighed. One hemisphere was placed in
500µl of 50% trichloroacetic acid (TCA) solution and homogenized for 1 minute.
Following centrifugation, the dye was extracted and diluted 1:3 in ethanol
(ETOH). To determine the concentration of Evan’s blue dye in samples, the
fluorescence of each sample was read on a fluorescent spectrophotometer
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(Hitachi F-2000; excitation of 620nm and emission at 680nm) and the
concentration calculated based on external standards (100-500 ng/ml) per gram
of tissue.

A one-way ANOVA was performed to determine statistical significant

at the p<0.05 level, with Tukey’s Multiple comparison’s post-hoc test.
Cytokine Assays
To estimate the concentration of cytokines within the brain parenchyma, a
Bio-Plex multiplex cytokine assay kit was used on 3mos. 3KO, PPT1-/-, 2KO,
and WT mice (Bio-Rad laboratories, Hercules, CA). The ELISA-based cytokine
assay uses fluorescently labeled beads coated with cytokine-specific antibodies
to detect cytokine levels in tissues (Hulse et al., 2004). The 23-plex sample kit
includes standards and antibodies for the following cytokines: IL1α, IL-1β, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, GCSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α.
Briefly, mouse brains were transcardially perfused with PBS and homogenized in
a solution consisting of 10 mM Tris, 150 mM NaCl, 1 mM Dithiotreitol, 0.2%
Triton and 20 l/ml of Protease Inhibitor Cocktail (#P8340, Sigma, St. Louis, MO).
The supernatant from brain homogenates was diluted to obtain a protein target
concentration of 0.5-1.0 mg/ml and stored at -70 C. For the multiplex assay, the
samples were processed as per the manufacturer’s instructions. The fluorescent
beads were incubated with the brain homogenates, washed and then incubated
with biotin-labeled antibody cocktail. The samples were then incubated with
streptavidin-PE and the fluorescence values were read and analyzed by the flow
cytometry based Bio-Plex 2200 system (Bio-Rad laboratories, Hercules, CA).
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The concentration of the cytokine in each sample was estimated by using the
standard curve generated for each cytokine by the standards supplied in the kit.
Immunohistochemistry
Triple KO, 2KO, PPT1-/- and WT mice were sacrificed via a lethal injection
of euthasol and transcardially perfused with phosphate buffered saline (PBS)
until the liver was clear. The brains from 1, 3, 5, and 6 and 7 months old mice
were removed and fixed in 4% paraformaldehyde in phosphate buffer for 48
hours. Subsequently, the brains were cryoprotected with 30% sucrose in trisbuffered saline (TBS) and imbedded in OCT.

Brains were sectioned in the

coronal plane throughout rostral-caudal axis using a freezing cryostat. Adjacent,
free floating sections were stained with the following antibodies: rat anti-CD31
(PECAM; 1:50, BD Pharmingen), rat anti-CD45 (1:50, BD Pharmingen), rat antiCD3 (1:200; Abcam), and rabbit anti-Aquaporin 4(1:1000; Chemicon). Briefly,
sections were washed in tris-buffered saline (TBS), incubated in 1% H2O2
(Sigma) to quench endogenous peroxidase activity, and rinsed thoroughly in
TBS.

The tissue was blocked for 1 hour in 10% normal goat serum (NGS;

Sigma), 0.25% Triton X-100 in TBS. Sections were incubated overnight at 4˚C in
primary antibodies in 5% NGS, 0.2% Triton X-100 in TBS. The following day the
sections were rinsed in TBS and incubated in secondary antibodies (1:200;
Vector Labs) in 10% NGS, 0.1% Triton X-100 in TBS for 75 minutes. The tissue
was rinsed in TBS and then incubated in a peroxidase conjugated avidin-biotin
complex (1:200; Vectastain Elite ABC kit, Vector Labs) for 1 hour at RT.
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Antibody immunoreactivity was visualized with 3’-3’ diaminobenzidine and H2O2
(DAB kit; Vector Labs) in TBS. Sections were dehydrated and coverslipped.

Results
Longevity
While WT mice live a normal lifespan, the 3KO and PPT1-/- mice
experience a premature death mimicking a clinical feature of disease in INCL

Figure 1. Lifespan of the GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mice. The 3KO mice die
earlier than the 2KO, PPT1-/-, or wild type mice. The 3KO and PPT1-/- die by 27 weeks and
33 weeks, respectively. Furthermore, the 50% mortality rate for 3KO averages 20 wks while
the PPT1-/- mice is 30 wks.

(Figure 1).

All 3KO and PPT1-/- mice die by 27 weeks and 33 weeks,

respectively. Furthermore, the 50% mortality for the 3KO is 20 weeks of age
compared to 30 weeks for the PPT1-/- mice. Thus, the 3KO mice die earlier than
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the PPT1-/- mice, in addition to the WT and 2KO mice. This demonstrates an
accelerated disease course in the 3KO mice compared to the PPT1-/- mice.
Brain atrophy
Brain weights were used as a marker of overall brain atrophy. Brains from
3KO, 2KO, PPT1-/-, and WT mice were weighed at 3, 5, and 6 mos. of age
(Figure 2). At 3 mos. of age, there was no significant difference in brain weights
among the groups tested (p<0.30). Conversely, there was a significant decrease
in brain weight at 5 mos. of age in the 3KO mice (p<0.027) compared to the
either PPT1-/-, 2KO, or WT mice. On average, the 3KO brains weighed 13.6%

*

*

Figure 2. Brain atrophy in the GFAP-/-, Vimentin-/-, PPT1-/- (3KO) mice. At 3 mos. of age,
there is no significant difference in the brain weights between 3KO, 2KO, PPT1-/-, and WT
mice. However, the 3KO brains weigh significantly less than PPT1-/-, 2KO, and WT mice at 5
mos. of age suggesting atrophy occurs at this time. By 6 mos. of age, both the 3KO and
PPT1-/- brains weigh significantly less than WT and 2KO brains ( * = p<0.05).
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less than WT brains at 5 mos.

By 6 mos. of age, there was a significant

decrease in the brain weights of both the 3KO and PPT1-/- mice compared to
WT and 2KO mice (p<0.001). The 3KO and PPT1-/- brains decreased in weight
by 20% and 17%, respectively, when compared to WT brains.

These data

demonstrate an overall brain atrophy in 3KO mice beginning at 5 mos. of age,
which precedes the atrophy seen in the PPT1-/- brain at 6 mos. of age.
Cortical Thinning
Upon gross examination, the primary visual cortex (V1) of 3KO and PPT1/- mice appeared atrophied in comparison to 2KO and WT brains (Figure 3A).

A

B
p<0.001

WT

2KO

PPT-/-

3KO

Figure 3. Cortical thinning in the GFAP-/-, Vimentin-/-, PPT1-/- mice. (A) Representative images
from the visual cortex (V1) of WT, 2KO, PPT1-/-, and 3KO mice. Upon gross examination, V1 of 3KO
and PPT1-/- mice appeared atrophied in comparison to 2KO and WT brains. (B) Quantification of
cortical thickness in the WT, 2KO, PPT1-/-, and 3KO mice. There is a significant difference in cortical
thickness between all groups (p<0.0001). The visual cortex of 3KO mice is thinner than the V1
cortex of PPT1-/-, 2KO, and WT mice.

Therefore, we measured cortical thickness in V1 at 6 mos. of age in the 3KO,
2KO, and WT mice (Figure 3B). There was a significant difference in cortical
thickness between all groups measured (p<0.001). At 6 months of age, the 3KO
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mice had a mean cortical thickness of 533.2µm, compared to WT, 2KO, and
PPT1-/- brains, which were 719.6µm, 687.8µm, and 583.2µm, respectively.
Thus, there was a 25.9% decrease in cortical thickness of 3KO brains compared
to WT, while the PPT1-/- brains only suffer an 18.9% loss. Therefore, cortical
thinning in the 3KO is more severe than in the PPT1-/- or 2KO brains when
compared to WT.
Autofluorescent Accumulation
Accumulation of an autofluorescent substrate throughout the neuraxis is a
hallmark of INCL. Therefore, we investigated whether the 3KO brains had a
demonstrable load of autofluorescent material. Qualitatively, the 3KO and PPT1/- brains both contained autofluorescent storage material throughout the brain at
6 mos. of age. Autofluorescent substrate accumulated intracellularly in the 3KO
brain in a pattern similar to the PPT1-/- mouse (Figure 4A). A low level of
autofluorescent material was detected in the WT and 2KO, largely due to the
presence of autofluorescent red blood cells contained within the vasculature. To
determine

the

level

of

storage

material

in

the

CNS,

we

quantified

autofluorescence in the S1BF cortex of 3KO, 2KO, PPT1, and WT brains (Figure
4B). There was a significant increase (p<0.001) in autofluorescent accumulation
in both the PPT1-/- and 3KO brains compared to WT and 2KO. Furthermore,
there was a significant difference (p<0.0023) in the levels of autofluorescent
substrate in PPT1-/- and 3KO mice. More specifically, there was a 21% increase
in autofluorescence in the S1BF cortex of PPT1-/- mice compared to the 3KO
mice.
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Figure 4. Autofluorescent accumulation in the GFAP-/-, Vimentin-/-, PPT1-/- mice.
(A) Representative images of the somatosensory barrel field (S1BF) cortex in WT, 2KO,
PPT1-/-, and 3KO mice. Autofluorescent accumulation is present in both the 3KO and
PPT1-/- mice compared to the 2KO and WT brains. (B) There is a significant increase
(p<0.0001) in autofluorescent material in the PPT1-/- and 3KO mice compared to WT and
2KO mice. Interestingly, there is a significant decrease in autofluorescent load in the 3KO
mice compared to PPT1-/- mice (p<0.0023).
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Neurodegeneration
Given that neuronal loss is a hallmark feature of INCL, de Olmos cupric
silver staining was performed to assess the levels of neurodegeneration present
in the 3KO brains (Figure 5). When neurons undergo degeneration in the CNS,
they have a high binding affinity for silver causing both cell bodies and processes
to appear ‘blackened’ with this staining method. Thus, we first examined the
distribution of silver staining in the 3KO brain. Previous studies in the PPT1-/mice demonstrated the neuronal loss was largely found within the thalamus,
cortex, cerebellum, and hippocampus of aged mice (Griffey et al., 2005; Griffey
et al., 2006). In fact, the distribution of neurodegeneration in the 3KO brains
mirrored the pathology observed in the PPT1-/- brains. Globally, degenerating
neurons were present within the cortex, thalamus, hippocampus, and cerebellum
at 5 mos. of age (Figure 5A). In the cortex, ‘blackened’ cell bodies of dying
neurons are primarily localized to layers II & V while degenerating axons litter the
cortex. Diffuse staining throughout the thalamus is present, most notably in the
afferent and efferent fibers associated with thalamic nuclei. Intense staining is
found the cerebellum, with the cerebellar white matter densely stained.
Additionally, darkened cell bodies are found within the Purkinje cell layer
demonstrating degeneration in the 3KO cerebellum similar to the PPT1-/- brain.
Darkly stained profiles were also found in the CA1 field of the hippocampus as
well as degenerating processes filling the stratum radiatum. Based on these
findings, the distribution of neurodegeneration within the 3KO brains mimics the
observations found in the PPT1-/- mice.
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Figure 5. Neurodegeneration, as visualized by silver degeneration staining, in the GFAP-/-,
Vimentin-/-, PPT1-/- mice. (A) Representative images from the cortex, thalamus, cerebellum, and
hippocampus of 5 mo. old 3KO mice. Darkly stained cell bodies are present in the cortex and CA1
field of the hippocampus, while degenerating axons are present in the thalamus and cerebellar
white matter tracts. (B) Time course of neurodegeneration in the 3KO mouse. As the 3KO mice
age, the intensity and distribution of silver staining increases demonstrating an increase in
neurodegeneration. Interestingly, the level of degeneration in a 7 mos. PPT1-/- brain appears
comparable to the 3KO at 5 mos. of age. (C) Comparison of silver staining at 5 mos. of age in the
WT, 2KO, PPT1-/-, and 3KO mice. At 5 mos. of age, there is no staining within the WT or 2KO
brains. Staining in the PPT1-/- brain is localized to the corpus callosum, hippocampus, and
thalamus. In the 3KO brain, staining in these regions appears more intense, suggesting an
accelerated disease course in the 3KO brains.
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In addition to the regional distribution of neurodegeneration, we also
investigated the temporal progression of disease in the 3KO at 3, 5, and 6 mos.
(Figure 5B).

As the 3KO mice age, there is increase in silver degeneration

staining throughout the thalamus, hippocampus, and cortex.

Although silver

staining is present in the cortex and thalamus at 3 mos. of age, the hippocampus
is relatively spared. As the mice age, darkly stained profiles are apparent in the
hippocampus as well as the cortex. Similarly, staining in the corpus callosum
increases in intensity by 5 mos. By 6 mos. of age, the entire 3KO brain appears
blackened. In areas where individual degenerating axons were easily reconciled
(i.e. pyramidal neurons from the CA1 field of the hippocampus), the 6 mos. 3KO
brains now appear densely stained and indiscernible. The neurodegeneration
occurring in the 6 mos. 3KO is more advanced than a PPT1-/- brain at 7 mos. of
age (Figure 5B), again illustrating the accelerated disease phenotype in the 3KO
mice.
In addition to characterizing the distribution and progression of pathology
in the 3KO, we sought to compare the relative severity of pathology in the 3KO
mouse to the PPT1-/-, 2KO, and WT mice (Figure 5C). Little or no silver staining
was present within either the 2KO or WT brains. In the PPT1-/- brain, blackened
cellular profiles were apparent within the cortex and CA1 field of the
hippocampus. In addition, blackened axonal projections filled the thalamus and
corpus callosum. Qualitatively, the same pattern of staining was present in the
3KO mice but it appears to be stained more intensely. In particular, the corpus
callosum and statum radiatum appeared more densely stained in the 3KO
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compared to PPT1-/- mice. Furthermore, the distribution and intensity of staining
increased

in

the 3KO

cortex

and

thalamus.

Overall,

the

level of

neurodegeneration in the 3KO brains seems greater than that of the PPT1-/brains.
Immune cell infiltration
H&E stained sections of 3KO brains displayed a small cell infiltrate not
present in either the PPT1-/-, 2KO, or WT brains (data not shown).
Hypothesizing the small cell infiltrate was composed of blood-derived leukocytes,
we performed CD45 staining, a pan-leukocyte marker, in the 3KO, 2KO, and WT
brains (Figure 6). At 5 mos. of age, the 3KO brains had a qualitative increase in
the number of CD45-positive profiles throughout the neuraxis compared to PPT1/- and controls (Figure 6A). Although some CD45-positive profiles were present
within the PPT1-/- brains, the staining was considerably less than that of the 3KO
brains. Furthermore, CD45+ staining was absent from the WT controls.
At higher magnification, it was clear that the CD45-positive cells within the
3KO brains were morphologically diverse (Figure 6B, C, D). Some of the cells
resembled microglia (Figure 6B), granulocytes or macrophages (Figure 6C), and
lymphocytes (Figure 6D). To ascertain what CD45 population was invading the
brain parenchyma, we stained for different cell lineages with lineage specific
markers.

Using Iba-1 staining for microglia or brain macrophages, we

demonstrated a large number of Iba-1 positive cells in both the PPT1-/- and 3KO
brains (Figure 6E).

The intensity of staining per cell appeared qualitatively

increased in the 3KO brains, although no overt increase in the number of cells
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Figure 6. Immune cell infiltration into the 3KO CNS. (A) CD45, a leukocyte marker, staining
in the 5 mo. 3KO, 5 mo. PPT1-/-, and 7 mo. WT cortex. Notice the large number of CD45+ cells
within the 3KO cortex in comparison to either the PPT1-/- or WT brains. At higher
magnification, the CD45+ cells appeared to be morphologically similar to microglia (B),
granulocytes or macrophages (C), and lymphocytes (D). (E) Staining with lineage-specific
markers demonstrated a large population of Iba-1+ microglia and macrophages within the
PPT1-/- and 3KO brains. Interestingly, there was a large population of CD3+ T cells (small
intensely staining foci) within the 3KO brains, when compared to PPT1-/- and WT.
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stained was appreciable.

Interestingly, CD3 staining, a T cell marker,

demonstrated a marked increase in the number of CD3+ cells within the 3KO
brains compared to either PPT1-/- or WT (Figure 6E). Although CD3+ cells were
present in low amounts in the PPT1-/- brain, the number of CD3+ profiles in the
3KO was considerably higher than in PPT1-/- mice.
Blood brain barrier permeability and the gliovascular unit
To detect possible perturbations in the blood brain barrier (BBB), a
quantitative Evan’s blue (EB) assay was employed (Figure 7). When delivered
intravenously, EB binds albumin and circulates throughout the blood stream. If
the BBB is disrupted due to an insult or injury, the EB/albumin complex will cross
the BBB into the brain parenchyma and the levels of EB within the brain can be
quantified. PPT1-/-, 3KO, and WT mice were injected intravenously with EB dye
and the concentration in the brain was analyzed. To serve as a positive control
for BBB permeability, WT mice were given middle cerebral artery occlusions
(MCAO), a procedure known to disrupt the BBB (Belayev et al., 1996). There
was a significant (p<0.001) increase in EB concentration within the MCAO brain
compared to the 3KO, PPT1-/-, or WT. Interestingly, there was no significant
difference (p< 0.1798) in EB concentration in either 3KO or PPT1-/- brains
compared to WT mice, suggesting no overall perturbation of the BBB in the 3KO
mice.
Although no gross disruption of the BBB was detected in the 3KO, we
investigated the structural integrity of the gliovascular unit. We immunostained 6
mo. old 3KO and WT mice for aquaporin 4 and CD31 (PECAM). Qualitative
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Figure 7. BBB integrity in the 3KO mouse. (A) An Evan’s blue
assay was performed to assess BBB permeability in the 3KO, PPT1-/-,
and WT mice. There was no significant difference in the amount of
Evan’s blue detected in the brains of 3KO compared to PPT1-/-, or WT
mice. A middle cerebral artery occluded (MCAO) mouse served as a
positive control for the assay. (B) Alterations in the gliovascular unit of
3KO mice was evident with aquaporin 4 (AQP4) and CD31 (PECAM)
staining. There was a redistribution in AQP4 staining in the 3KO mice
compared to WT. Similarly, the PECAM staining illustrated changes in
the vascular in 3KO brains.
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differences in aquaporin 4 staining, a water channel localized to the endfeet of
astrocytes, were apparent in the 3KO mice compared to WT (Figure 7B). In the
WT cortex, aquaporin staining appears to outline the vasculature and localizes to
the junction of the astrocytic endfeet and blood vessels.

In the 3KO mice,

however, this intimate junction between the astrocytic endfeet and vasculature
appears disrupted and is replaced by a more diffuse pattern of aquaporin 4
staining throughout the cortex. It remains unclear whether there is an actual
decrease in the amount or merely an altered distribution of aquaproin 4 in the
3KO brains. Alterations in CD31 (PECAM) staining were also appreciable in
3KO brains compared to WT. In the WT brains, CD31 demarcated the vascular
bed traversing through the CNS. Although the size of vessle differed from vessel
to vessel, the diameter of individual blood vessels appeared uniform in the WT
brains (Figure 6B; inset). Conversely, regions of CD31+ vessels in the 3KO mice
appeared either shrunken, dysmorphic or “pinched” (Figure 7B; inset). Together,
CD31 and aquaporin 4 staining demonstrates changes in the gliovascular unit of
3KO mice.
Cytokine Levels
A panel of 23 cytokines was simultaneously evaluated in 3 mos. old 3KO,
PPT1-/-, 2KO, and WT brains using a Bio-Plex cytokine assay system (Bio-Rad).
Out of the 23 cytokines assayed, 13 analytes displayed increased expression in
both 3KO and PPT1-/- mice compared to WT (Figure 8).

In all cases, cytokine

elevation in the 3KO mice was greater than the PPT1-/- mice. Many of the
upregulated molecules (i.e. IL-3, IL-5, IL-6, IL-13, etc.) are traditionally secreted
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Figure 8. Elevated cytokine levels in the 3KO brains. The brains from 3 mos. old 3KO, 2KO,
PPT1-/-, and WT mice were simultaneously assayed for 23 different cytokines. Of those
assayed, 13 cytokines were upregulated in the 3KO (green) and PPT1-/- (red) brains normalized
to WT. The 3KO brains contained elevated levels of cytokines in comparison to PPT1-/-. IL-17,
IFN-g, MIP-1β, and RANTES demonstrated greater than 15-fold higher cytokine levels than WT.

by T cells and stimulate additional immune cell activation. In addition, a number
of the cytokines, such as MCP-1, MIP-1α, and MIP-1β, are secreted by
monocytes and activate both monocytes as well as other immune cells. There
were 4 cytokines with greater than a 15-fold change in levels compared to WT
brains.

These molecules include IL-17, IFN-g, MIP-1β, and RANTES, all of

which a pro-inflammatory molecules.
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Discussion
Previous research demonstrated that the first histopathological change
observed in the mouse model of INCL is astrocyte activation.

Astrocyte

activation, as defined by GFAP upregulation, is present as early as 1-3 mos. of
age in the thalamus, cortex, and cerebellum of PPT1-/- mice (Kielar et al., 2007;
Macauley et al., 2009). Subsequent to this early stage gliosis, there is significant
neuronal loss in the same regions. Therefore, we hypothesized that astrocyte
activation plays a role in the disease pathogenesis of INCL.

However, one

question remained: was astrocyte activation a helpful or harmful process in
INCL?
To investigate the role of astrocyte activation in INCL, we created the
GFAP-/-, Vimentin-/-, PPT1-/- triple knockout (3KO) mouse. Since astrocytes
first respond to injury by upregulating the intermediate filament proteins, GFAP
and vimentin, increased GFAP expression is viewed as the classic sign of
astrocyte activation or gliosis (Kalman, 2004; Pekny and Nilsson, 2005;
Sofroniew, 2005). In addition, increased expression of IFs in activated astrocytes
correlates with a change in the molecular profile and function of astrocytes.
Typically responsible for homeostatic maintenance and structural support in the
CNS (Ransom et al., 2003), astrocytes take on the additional role of an
inflammatory-mediating cell responsible for cytokine secretion, scar formation,
and the clearance of debris in the context of gliosis. Since there was a strong
correlation between the upregulation of IFs and the functional shift in astrocytes,
we hypothesized that by knocking out GFAP and its co-polymerizing IF protein,
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vimentin, we would alter the manner in which astrocytes respond to injury. Thus,
by creating the 3KO mouse, we could evaluate whether astrocyte activation is
helpful or harmful in a mouse model of INCL.
Our first goal was to investigate whether the classic features of INCL were
reproduced in the 3KO mice. Since the brains from INCL patients display an
overall atrophy, cortical thinning, autofluorescent accumulation, and widespread
neurodegeneration, we chose to investigate these pathological changes in the
3KO mouse. Interestingly, we found that the 3KO mouse displayed the same
pathological features as the PPT1-/- mice and patients with INCL. The 3KO mice
suffered premature death by 28 weeks of age compared to 2KO and WT mice.
Similarly, there was both a global brain and regional atrophy observed in the 3KO
mice compared to controls at an end stage of disease. Furthermore, the brains
from 3KO mice displayed an increase in autofluorescent material, a hallmark of
INCL.

Most importantly, silver staining demonstrated that the regional

distribution of neurodegeneration matched the pattern of pathology seen in the
PPT1-/- or INCL brains. These findings demonstrate that in the absence of the
IF proteins, GFAP and Vimentin, the pathological changes associated with INCL
are reproduced in the 3KO mouse. Thus, the introduction of two novel mutations
(i.e. GFAP and Vimentin deficiencies) onto the PPT1-/- background did not
create a novel disease phenotype. Therefore, the 3KO mouse is an excellent
model to investigate the effects of altered astrocyte activation on clinical features
of INCL.
Although the hallmarks of INCL are recapitulated in the 3KO mice, the
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progression of disease is altered compared to the PPT1-/- mice. In the absence
of the IF proteins, GFAP and Vimentin, the time course of disease is accelerated
compared to the PPT1-/- mice. On nearly every parameter measured, the 3KO
mice displayed either an early onset of disease (i.e. premature death & brain
atrophy) or an increased severity of disease at a particular time point (i.e. cortical
thinning & neurodegeneration). This demonstrated that astrocyte activation is a
protective feature of disease in INCL. In the absence of GFAP and Vimentin
upregulation, the disease phenotype present in the PPT1-/- mice displays an
early onset and increased severity.
The one notable exception to the accelerated disease course in the 3KO
mouse is autofluorescent accumulation. Although both the 3KO and PPT1-/brains demonstrate an increase in autofluorescent storage compared to 2KO and
WT mice, the 3KO mice have significantly less material compared to PPT1-/mice. This finding has several possible explanations. Most likely, there could be
less autofluorescent material in the 3KO mice because there is greater
neurodegeneration resulting in fewer cells to accumulate stored substrates.
Conversely, it is plausible that the 3KO mice do not accumulate storage
pathology as rapidly as PPT1-/- mice. Thus, the causal relationship between
autofluorescent accumulation and neurodegeneration remains poorly understood
and warrants further study.
In an effort to investigate the underlying mechanism causing the
accelerated phenotype in 3KO mice, we investigated the presence of
inflammatory cells within the 3KO brains. In fact, we detected the presence of
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CD45-positive cells, or leukocytes, in the brains of 5-month-old 3KO mice, a
phenomenon absent in the PPT1-/- brains at a comparable age. Interestingly, if
PPT1-/- brains at 7 mos. of age are stained with a CD45 antibody, CD45+
leukocytes are present in the brain. Again, suggesting that the same disease
processes are present in the 3KO but exacerbated when compared to the PPT1/- mice. The CD45+ cells within the 3KO brains were morphologically diverse.
Through cell lineage-specific markers, CD3 and Iba-1 staining, we showed a
large T cell and monocyte population within the 3KO brains, respectively. We
hypothesize that the infiltration of T cells and monocytes is contributing to the
accelerated disease course observed in the 3KO mice. Other neurodegenerative
disorders, such as multiple sclerosis (McCandless and Klein, 2007), Krabbe
disease (Wu et al., 2001), and West Nile viral infection (Shrestha et al., 2003),
demonstrate the presence of peripheral immune cells in the CNS and it is
hypothesized that this phenomenon is playing an active role in disease
pathogenesis (Chavarria and Alcocer-Varela, 2004; Lucas et al., 2006).
To examine the possible mechanisms for T cell and monocyte entry into
the CNS, our work focused on the blood brain barrier in the 3KO mice.
Interestingly,

the

astrocytes

that

first

display

an

increase

in

GFAP

immunoreactivity are cells in intimate contact with the vasculature (data not
shown). Postulating that the integrity of the BBB was compromised in the 3KO
mice, we investigated the ability of a large EB-albumin complex to cross the BBB.
Interestingly, no gross perturbation of the BBB was appreciable in either the 3KO
or PPT1-/-. We further examined the BBB integrity by investigating the structural

81

composition of the gliovascular unit. By staining the 3KO and WT brains with
aquaporin 4 and CD31 (PECAM), we demonstrated both a redistribution in
aquaporin 4 staining as well as dysmorphic blood vessels in the 3KO brain. This
suggests that there are alterations in the gliovasucular unit in the 3KO mice when
compared to WT. Changes in both aquaporin 4 and PECAM expression have
been implicated in neurodegenerative diseases and disruptions in the BBB that
facilitate leukocyte entry into the CNS (Chavarria and Alcocer-Varela, 2004;
Nesic et al., 2006). Based on these observations, we hypothesize that IFs are
necessary for maintaining the gliovascular unit during astrocyte activation. In the
absence of intermediate filament proteins, the structural organization of the BBB
becomes compromised and allows for leukocyte entry into the CNS, thus
exacerbating disease.
Given that the BBB is not only a structural barrier but also a molecular
barrier, we sought to investigate the molecular signals expressed by the CNS
that are responsible for the influx of leukocytes. Therefore, we performed a BioPlex mouse cytokine assay, which screens the levels of 23 different cytokine
simultaneously. At 3 mos. of age, there was a notable increase in 13 cytokines
in both the 3KO and PPT1-/- brains. In all cases, cytokine evaluations in the
3KO mice were greater than those seen in PPT1-/- mice. In addition to changes
in the gliovascular unit, this finding demonstrates that increased cytokine
expression could be responsible for the influx of peripheral immune cells into the
CNS.
Of the cytokines with increased expression levels, many of the molecules
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(i.e. IL-3, IL-5, IL-6, IL-13, etc.) are traditionally secreted by T cells and
responsible for the stimulation and activation of other immune cells (Doan et al.,
2007; Dong and Benveniste, 2001; Rengarajan et al., 2000). Similarly, a number
of the cytokines normally secreted by monocytes/macrophages, such as MCP-1,
MIP-1α, and MIP-1β, are responsible for the activation of other immune cells
(Cocchi et al., 1995). Given the large T cell and monocyte populations within the
3KO brains, it is not surprising that this set of cytokines is upregulated.
Interestingly, several of the cytokines expressed in the 3KO and PPT1-/- brains
are also routinely expressed by astrocytes during neuroinflammation, including
IL-6, KC, GM-CSF, RANTES, and MCP-1 (Dong et al). Although it is unclear
what cells types are responsible for the elevated cytokine levels, it is clear that a
large neuroinflammatory response is occurring within the CNS of 3KO brains.
Of the cytokines upregulated, there were four cytokines with a greater
than 15-fold increase in expression. These molecules include IL-17, IFN-g, MIP1β, and RANTES.

Not surprisingly, IL-17, a pro-inflammatory molecule

responsible for the induction of numerous cytokines (e.g. IL-6, GM-CSF) and
chemokines (e.g. IL-8, MCP-1) in a variety of cell types (e.g. endothelial cells,
macrophages), demonstrated a 17.9-fold increase in cytokine levels in the 3KO
brains.

Similarly, interferon gamma (IFN-g), one of the most common pro-

inflammatory cytokines in the CNS during disease or injury, displayed 23.4-fold
change compared to WT. IFN-g is known to be a potent inducer of class II MHC
expression in astrocytes, which is subsequently responsible for the activation of
both T cells and macrophages. Furthermore, production of IFN-g can damage
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the BBB due to cytotoxic effects on endothelial cells (Chavarria). Produced by
macrophages, MIP-1β is a chemotactic cytokine responsible for the recruitment
of granulocytes as well as the stimulation and release of additional cytokines by
monocytes. Interestingly, RANTES, often expressed by astrocytes, is another
chemotactic cytokine responsible for the recruitment of T cells and other
leukocytes to sites of inflammation. Given the high level of expression of these
four cytokines, it is not surprising that an invading leukocyte population was
detected in the brains of the 3KO mice or that an increase in neurotoxic insults
was appreciable in the CNS.
The goal of this study was to investigate the role of astrocyte activation,
as defined by GFAP upregulation, in INCL. To do so, we created the GFAP-/-,
Vimentin-/-, PPT1-/- triple knockout mouse and investigated the effects of
knocking out the intermediate filament proteins on the disease progression
associated with INCL. Although we found that PPT1-/- mice lacking GFAP and
Vimentin displayed the classic features of INCL, the 3KO mice displayed a more
accelerated course of disease compared to PPT1-/- mice alone. The 3KO mice
displayed either an early onset of disease (i.e. premature death & brain atrophy)
or an increased severity of disease at a particular time point (i.e. cortical thinning
& neurodegeneration) when compared to PPT1-/- mice.

To determine the

underlying mechanisms contributing to this accelerated phenotype, we found a T
cell and monocyte population in the brains of 3KO mice. Although there was no
overt disruption in the BBB, there were alterations in the gliovacular unit that may
be responsible for leukocyte infiltration. In addition to structural changes in the
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BBB, we demonstrated increased cytokines are potentially responsible for the
increased neuroinflammation in 3KO and ultimately the accelerated disease
course. Taken together, these data suggest that astrocyte activation, as defined
by GFAP upregulation, plays a protective role in a mouse model of INCL.
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Chapter Four

Summary, Conclusions,
and Future Directions
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Summary and Conclusions
Infantile neuronal ceroid lipofuscinosis (INCL) is a rare lysosomal storage
disorder typified by prominent CNS involvement (Hofmann et al., 1999; Hofmann
and Peltonen, 2001; Vesa et al., 1995). INCL is caused by an enzyme deficiency
in the lysosomal hydrolase, palmitoyl protein thioesterase 1 (PPT1).

In its

absence, all cells throughout the CNS and viscera accumulate autofluorescent
material (i.e. GRODs) to varying extents (Das et al., 1998; Hofmann et al., 2002;
Mitchison et al., 1998; Mitchison et al., 2004; Vesa et al., 1995).

Normally

diagnosed by 1.5 years of age, patients with INCL present with clinical features
such as blindness, seizures, motor deficits, retinal defects, and mental
retardation. Underlying these clinical manifestations, pathological changes in the
brain

include

an

overall

brain

atrophy,

cortical

thinning,

neurodegeneration, astrocyte activation, and microglial reactivity.

widespread
Invariably,

INCL is fatal and leads to death by 6 years of age (Haltia et al., 1973a; Haltia et
al., 1973b; Haltia et al., 1995; Hofmann and Peltonen, 2001; Vanhanen et al.,
1997). Currently, there is no efficacious treatment available for INCL.
Gupta and colleagues (2001) created a mouse model of INCL, the PPT1-/mouse. Initial characterization studies suggested that the mouse model of INCL
recapitulates the human course of disease quite well(Bible et al., 2004; Griffey et
al., 2004; Griffey et al., 2005; Griffey et al., 2006; Gupta et al., 2001). At an end
stage of disease, the PPT1-/- mice suffered brain atrophy, cortical thinning,
widespread neurodegeneration, glial activation, retinal defects, motor deficits,
and seizure activity; features similar to those found in patients with INCL.
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Based on these results, we believe the PPT1-/- mouse is a valuable tool
for investigating the disease pathogenesis of INCL. Although the pathology of
INCL patients at autopsy is well described, the underlying progression of
pathology remains poorly understood. Thus, the first goal of this work was to
investigate the temporo-spatial progression of cellular pathology and behavioral
deficits in the PPT1-/- mouse. By gaining a better understanding of disease
pathogenesis in a mouse model of INCL, we will be able to identify possible
areas of therapeutic intervention for treatment of the human course of disease.
Summary of characterization studies
The goals of the characterization studies in the PPT1-/- mice were twofold. The initial characterization studies in the PPT1-/- mouse investigated the
pathology of the forebrain and demonstrated that many of the pathological
changes seen in patients with INCL were mirrored in the PPT1-/- mice.
Therefore, the first goal of the characterization studies was to expand the
forebrain characterization to investigate the temporal changes as they occur
during disease progression. These studies were carried out in collaboration with
Jonathon Cooper’s Lab at Kings College – London (Kielar et al., 2007).
The first pathologic change observed was astrocyte activation in both the
cortex and thalamus of PPT1-/- mice at 3 mos. of age. Subsequently, there was
localized neuronal loss in thalamic nuclei that coincide with the regions where
astrocyte activation occurred.

Beginning at 3-5 months of age, the thalamic

regions affected by neuronal loss include the LGN, VPL/VPM, MGN, and Rt.
Following neuronal loss in the thalamus, cortical atrophy and neuronal loss

88

occurred in the cortical relays of PPT1-/- mice at 5-7 mos. of age. These regions
included both the visual and somatosensory cortex, which receive reciprocal
input from the thalamus. Neurodegeneration within both the thalamus and cortex
correlated with an increase in microglia reactivity beginning at 5 mos. of age.
Similarly, the onset of seizure activity and changes in the interictal EEG pattern
occurred at 7 mos. of age, coinciding with neuronal loss and glial activation within
the cortex and thalamus. When taken together, this study identified a timeline for
pathological changes within the forebrain.

First, astrocyte activation occurs

followed by neuronal loss in thalamic nuclei. Surprisingly, neurodegeneration
and atrophy occur secondarily in the cortex to the thalamus. Finally, widespread
microglial activation and functional deficits occur in the PPT1-/- brain.
The main goal of our characterization studies was to focus attention on the
cerebellum (Macauley et al., 2009). Motor deficits (Santavuori et al., 1974) and
cerebellar atrophy (Haltia et al., 1973a; Haltia et al., 1973b) are well documented
in patients with INCL, but no work was done to characterize the time course of
pathology within the PPT1-/- mouse. Therefore, we investigated the time course
of cerebellar disease progression and motor deficits in the PPT1-/- mouse.
Similar to the findings from the forebrain studies, the first pathological
change observed in the PPT1-/- cerebellum was astrocyte activation. As early as
1 month of age, there was an increase in GFAP staining throughout the vermis.
The intensity and distribution of GFAP staining increased as the mice aged.
Subsequent to astrocyte activation, there was neuronal loss in the PPT1-/cerebellum. At 3 mos. of age, degenerating Purkinje cells were present within
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the anterior lobes of the cerebellum. There was a trend towards a decrease in
total Purkinje cell number at 5 mos. with a significant loss in this population by 6
mos. of age. By 7 mos. of age, only 50% of all Purkinje cells remained in the
PPT1-/- cerebellum. Similarly, a significant decrease in granule cell number was
also seen at 7 mos. of age, but not prior to this late stage time point.
The scope of neurodegeneration occurring within the PPT1-/- cerebellum
was visualized by silver degeneration staining. In a 7 mo. old PPT1-/- brain,
parasagittal bands of degenerating Purkinje cells filled the cerebellar cortex of
the vermis and lateral hemispheres.

The molecular layer was littered with

fragmented dendritic arbors associated with dying Purkinje cell neurons.

In

addition to their dendritic arbors, the cerebellar white matter tracts displayed an
intense staining suggesting the afferant and efferent fibers of the cerebellum
were undergoing neurodegeneration.
In addition to astrocyte activation and widespread neurodegeneration at 7
mos. of age, there were pathological changes within the glial population of the
PPT1-/- mouse. There are numerous changes in the Bergmann glia suggestive
of astrocyte dysfunction or death. There are decreases or losses in markers like
S100β and glutamine synthetase.

Furthermore, there are decreases in

glutamate transporter staining, such as GLAST and to a lesser degree, GLT-1.
The loss of these markers demonstrates a primary pathology intrinsic to the
astrocyte that occurs in addition to early stage astrocyte activation. In addition to
the astrocytes, there is microglia activation beginning at 5 mos. of age as
visualized by F4/80 staining. The number, intensity and distribution of F4/80
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stained cells increase as the PPT1-/- mice age. Moreover, there is a shift in the
morphology of F4/80+ monocytes, from small, ramified microglia to larger, more
amoeboid shaped macrophages. Finally, a decrease in myelin is appreciable at
7 mos. of age in the cerebellar white matter tracts of PPT1-/- mice. The staining
for myelin appears less intense and patchy at an end stage of disease. Taken
together, these findings demonstrate that pathology within the PPT1-/cerebellum is not limited to the neuronal population.

Rather, there is

considerable pathology localized to the glial population, including the astrocytes,
microglia, and oligodendrocytes, in the PPT1-/- mice.
Finally, we sought to investigate how the changes in the underlying
pathology correlated with motor deficits in the PPT1-/- mice. A constant speed
rotorod paradigm demonstrated significant motor deficits in the PPT1-/beginning at 5 months of age. The performance of the PPT1-/- mice further
declined as the mice aged, with a nadir in performance by 7 months of age. The
alterations in motor function mirrored the Purkinje cell loss in the PPT1-/- mice.
Conclusions from characterization studies
The characterization studies provide a comprehensive time course of
disease progression in the PPT1-/- mice. These findings cause a shift in how we
view the pathogenesis of INCL. Historically, work performed on INCL patients at
autopsy brought focus to certain pathological changes within the brain, including
brain atrophy, cortical thinning, neuronal loss, and autofluorescent accumulation.
Although these pathological changes are rightfully hallmarks of INCL, our work

91

demonstrates that many of these features occur at the end stage of disease and
provide little insight into the evolution of pathology in this disorder.
First, the dogma surrounding this disease is very neuro-centric and gives
little attention to the profound glial involvement in this disease.

Our studies

demonstrate that not only is astrocyte activation the first pathological change
observed in INCL, but prominent glial involvement, including astrocytes,
microglia, and oligodendrocytes, is a key component to this disease.

Thus,

understanding the relative contributions of each cell type to disease pathology is
important for the development and direction of therapies (see Future Directions).
Secondly, given the data at autopsy and the functional deficits
experienced by INCL patients, much of the focus for therapeutic intervention has
centered on targeting the cortex. Since neurodegeneration and atrophy in the
cortex is a rather late stage phenomenon, intervention should occur earlier to
prevent the disease progression and in areas affected at the onset of disease.
Thus, interventions targeting astrocyte activation or the pathological changes in
the thalamus would be better suited for early interventions to maximize
therapeutic outcomes (see Future Directions).
Finally, these characterization studies demonstrate both the extent and
severity of disease in INCL. Patients with INCL suffer from a complex set of
clinical features, with extensive underlying pathology, which involves the majority
of the CNS. Thus, in order to properly treat these disorders, one form of targeted
therapy will not be sufficient.

To provide patients with a therapeutic benefit,
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multiple therapies aimed at a variety of disease pathologies and targets must be
employed (see Future Directions).
Summary of findings from the GFAP-/-, Vimentin-/-, PPT1-/- mice
Based on the finding that the first pathological change observed in the
PPT1-/- mouse was GFAP upregulation, therefore, we investigated whether
astrocyte activation and GFAP upregulation was helpful or harmful to the CNS in
INCL. To accomplish this, we created the GFAP-/-, Vimentin-/-, PPT1-/- triple
knockout (3KO) mouse by breeding the GFAP-/-, VImentin-/- double (2KO)
mouse to the PPT1-/- mouse (Gupta et al., 2001; Pekny et al., 1999). First, we
investigated the effects of knocking out GFAP and Vimentin on disease
parameters specific to INCL. Interestingly, we found that PPT1-/- mice lacking
GFAP and Vimentin displayed similar clinical features of INCL, but an
accelerated time course when compared to PPT1-/-, 2KO, or WT mice. The 3KO
mice died earlier than the PPT1-/-, 2KO, and WT mice. Moreover, the 3KO
brains atrophied quicker than PPT1-/- mice and controls. Both cortical atrophy
and neurodegeneration was more severe in 3KO mice compared to PPT1-/mice.

Thus, lacking the intermediate filament proteins, GFAP and Vimentin,

increased the pervasiveness of the INCL phenotype in the PPT1-/- mouse.
One possible explanation for this accelerated phenotype is due to the
influx of peripheral immune cells into the CNS of the 3KO mice. Normally absent
from the brain parenchyma, we found CD45-positive cells, or leukocytes, littering
the neuraxis of the 3KO brains.

Staining with cell lineage specific markers

illustrated the presence of CD3+ T cells and Iba-1+ macrophages and microglia
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in the 3KO brains, cells normally absent from a healthy CNS. Postulating that
the trafficking of leukocytes into the CNS is due to a perturbation of the BBB, we
investigated BBB integrity in the 3KO mice. We found no gross disruption in the
BBB of 3KO mice when compared with PPT1-/- or WT mice. However, we did
find structural alterations in the gliovascular unit of 3KO mice. There was a
redistribution of aquaporin 4 staining suggesting changes at the endfeet of 3KO
astrocytes. Furthermore, changes in PECAM staining demonstrated dysmorphic
blood vessels in the 3KO brain.

Together, these changes demonstrated

alterations in the gliovascular unit of 3KO mice. Since the BBB is both a physical
and molecular barrier in the CNS, we investigated the cytokine profiles in the
3KO brains in comparison to PPT1-/-, 2KO, and WT brains. In total, there were
13 cytokines upregulated in the 3KO and PPT1-/- brains. In every case, the
cytokines elevation was greater in the 3KO brains in comparison to the PPT1-/brains, in some cases up to a 40-fold increase compared to WT. The molecules
that were upregulated were largely pro-inflammatory molecules, chemokines for
lymphocyte and monocyte chemotaxis, as well as stimulatory molecules for
immune cell activation (Dong and Benveniste, 2001). Thus, in the absence of
the intermediate filament proteins, GFAP and Vimentin, there are signals within
the PPT1-/- mouse brains that actively recruit peripheral immune cells into the
CNS. We hypothesize this leukocyte infiltration exacerbates disease, specifically
the key features of INCL, in the 3KO mouse.
Conclusions from the 3KO mice
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Our studies in the 3KO mice show that astrocyte activation, as defined by
GFAP upregulation, is a protective process in INCL. In the absence of GFAP
and its copolymerizing IF, vimentin, the clinical features of INCL are the same in
the PPT1-/- and 3KO mice, but increase in severity causing the mice to suffer an
accelerated time course of disease.

Thus, we hypothesize that early stage

astrocyte activation is protecting the CNS from injury. Furthermore, our findings
suggest that the upregulation of IFs is necessary to maintain the structural
integrity of the blood brain barrier. And in their absence, leukocyte infiltration
from the periphery can occur and exacerbate CNS disease.
Although we described changes in the 3KO mice at an end stage of
disease, a thorough characterization of disease progression in the 3KO brains
should be performed (See Future Directions). By investigating temporal changes
in the 3KO mice, we could more thoroughly dissect the role astrocyte activation
plays in INCL. Specifically, if we are able to elucidate the function of astrocyte
activation at early time points, we might be able to gain a better understanding of
why astrocyte activation is the first change observed in INCL.
Beyond the role of astrocyte activation in INCL, these studies begin to
help elucidate the function of IF upregulation and its relationship to the function of
activated astrocytes in a model of chronic neurodegeneration. To date, little is
known about how IF upregulation and changes in the astrocyte’s morphology
relates to changes in cell function. Increased GFAP expression is always used
to demonstrate the presence of gliosis in CNS injury and disease, but little has
been done to show the functional significance of GFAP upregulation in the
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context of astrocyte activation.

Studies in the 3KO mice demonstrate a

correlative role between IF upregulation and the functional changes associated
with astrocyte activation.
By using the PPT1-/- mouse as our model of disease, we are also
investigating the role of astrocyte activation in a chronic, neurodegenerative
disorder of the CNS. Contrary to most of the work in the field, gliosis is normally
studied in response to an acute injury, including models of tramautic brain injury,
spinal cord lesion, acute infection, stroke, etc. It is most likely that the manner
with which the CNS responds to a focal, acute injury differs from its response to a
disease that is chronic, progressive, and widespread. Therefore, the 3KO mouse
provides us with an excellent tool to study the mechanisms by which reactive
astrocytes respond to a persistent, widespread disease (See Future Studies).
Finally, the 3KO mouse illustrates the dualistic nature of astrocyte
activation. Although astrocyte activation is overall a protective process in INCL,
there are aspects of this inflammatory process that are harmful to the CNS. For
example, we demonstrated in the PPT1-/- mouse that cytokines responsible for
leukocyte trafficking into the CNS are upregulated, while the 3KO model
illustrated how leukocyte entry into the CNS correlates disease severity.
Although gliosis is a process that adds protection to an injured brain (i.e. PPT1-/brain), there are aspects of gliosis that are suboptimal (i.e. cytokine production)
and can be targeted for therapeutic intervention (see Future Directions).
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Future Directions
Cell-specific contributions to INCL
Findings from the characterization studies performed in the PPT1-/- mice
chronicled the scope of pathology observed within the PPT1-/- brains. Although
neurodegeneration was a widespread, pervasive phenomenon in the PPT1-/brains, the extent of glial pathology had largely gone unappreciated until now.
We demonstrated that astrocytes, microglia, and oligodendrocytes are all
involved in the disease pathology of INCL.

Given that PPT1-deficiency is a

global phenomenon in INCL and that glial cells are reported to express PPT1,
perhaps it is not surprising that these cell types are equally as affected as
neurons within the CNS.

However, to move towards a treatment of INCL, it

would be beneficial to investigate the relative contribution of each cell type to
disease pathology. This would allow us to better target therapies to the correct
cell lineage.
Investigating the specific effects of cell lineages on INCL pathology is not
easy to accomplish. Attempting to isolate cell-specific effects in any disorder is
difficult but there are unique benefits and problems when studying lysosomal
storage diseases.

The main difficulty comes from the principle of “cross-

correction”. “Cross-correction” refers to the phenomenon in which lysosomal
enzymes are expressed within the target cell as well as secreted and taken up by
adjacent cells (Neufeld and Fratantoni, 1970). This allows for one cell to act as
an enzyme depot for all cell types within a microenvironment.
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Although the

principle of “cross-correction” is beneficial for treatment of INCL and other LSDs,
it complicates studying the cellular pathology in disease. Therefore, traditional
approaches using cell-specific promoters, transgenic technology, and the native
PPT1 protein are not suitable for investigating the cellular mechanisms of
disease in INCL.
One way to circumvent the principle of “cross-correction” is to develop a
means of sequestering lysosomal enzymes to prevent secretion. This would
allow for the specific correction of a target cell while keeping the diseased milieu
intact. Guarnieri and his colleagues (Guarnieri et al., 1993) identified a 35 amino
acid peptide sequence, containing the transmembrane domain and cytoplasmic
tail of lysosome-associated protein, LAMP-1, that is both necessary and sufficient
for lysosomal trafficking and retention. Therefore, it is possible to fuse a short
LAMP1 peptide sequence to the carboxyl terminus of PPT1 to effectively create a
lysosomal enzyme that is properly targeted to and retained by the lysosome
(Marathe et al., 2000). In fact, this approach was successfully used by Marathe
et al (2000) to create a mouse model of Niemann-Pick Type B disease.
Using this approach to sequester the PPT1 enzyme within a specific cell
type can then be used in concert with other standard gene transfer or transgenic
approaches to investigate cellular mechanisms of disease.

By sequestering

PPT1 within neurons or glia, it is possible to investigate the effects of selectively
restoring function to a specific cell lineage on both the pathological and functional
changes that occur in INCL. This will provide valuable insights into the process
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of disease pathogenesis as well as provide valuable targets for treatment of
INCL.
Further characterization of the 3KO mice
Our initial characterization studies in the 3KO mice provided insight into
the role of astrocyte activation in INCL. However, further work needs to be done
to investigate the temporal changes in the 3KO mice. Specifically, by clarifying
the function of astrocyte activation at early time points, we can gain a better
understanding of why astrocyte activation is the first change observed in INCL.
Determining the timeline for the structural and molecular changes in the BBB
would also provide insight into the role of activated astrocytes in INCL.

We

demonstrated that increased expression of cytokines leads to an influx of
peripheral immune cells into the CNS. However, we failed to demonstrate what
initial factors were responsible for cytokine upregulation and immune cell entry in
the CNS. By studying the 3KO pathology at earlier stages, we can uncover the
true functions of activated astrocytes and work towards a better definition of what
this process entails.
Effective targeting of therapeutics in INCL
Our characterization studies in the PPT1-/- mouse established a time line
of CNS pathology that challenged the current dogma in the field (Kielar et al.,
2007; Macauley et al., 2009). First, we showed that astrocyte activation occurs
early in the INCL, not later as was first hypothesized.

Secondly, we

demonstrated that the thalamus is the first area to undergo neuronal loss, with
degeneration in the cortex occurring secondarily.
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Lastly, we illustrated that

pathological changes in INCL are not limited to a neuronal population, but also
include glia. Based on these findings, we need to alter the framework by which
we develop and target therapies for INCL.
One of the most promising options for the treatment of LSDs is CNSdirected gene therapy (Daly and Sands, 1998; Macauley and Sands, 2009a;
Sands and Davidson, 2006; Sands and Haskins, 2008). Since INCL and most
other LSDs are due to a single enzyme deficiency, the simplest therapeutic
approach is enzyme replacement therapy (ERT). One way to ensure long-term,
CNS-directed enzyme replacement therapy is through the use of viral vectors.
Currently, adeno-associated virus (AAV) and lenti-viral vectors are touted as the
best options for CNS-directed therapy due to their tropism, long-term expression,
low immunogenicity, and transduction efficiencies.

However, many of the

researchers investigating the use of viral vectors for the treatment of NCLs
(Cabrera-Salazar et al., 2007; Griffey et al., 2004; Griffey et al., 2005; Griffey et
al., 2006; Passini et al., 2006) are using vectors with a tropism for neuronal
transduction (i.e. AAV-1, -2, and -5) (Burger et al., 2004). Given the significant
glial pathology in INCL and other forms of NCLs, findings from these therapy
studies could mistakenly suggest that viral vectors are inefficient therapeutic
tools. Therefore, experiments need to be performed that directly compare the
efficacy of glial- or neuronal-directed therapies for the treatment of INCL and
other LSDs.
Given that the pathology encompasses the entire neuraxis in INCL, the
task of directing therapies is quite challenging. In mouse models of LSDs like
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INCL, researchers are using novel therapies and methodologies in attempt to
treat the brain in its entirety (Bobo et al., 1994; Chen et al., 2009; Daly et al.,
2001; Dodge et al., 2009). Although this approach is ideal for disorders like
INCL, there may be alternative ways to slow disease progression until a
comprehensive treatment strategy is developed. For example, the first area to
display neuronal loss and glial activation is the thalamus, specifically the lateral
geniculate nucleus (LGN). Since previous research has demonstrated that early
interventions increase therapeutic efficacy (Cabrera-Salazar et al., 2007), the
thalamus should be targeted early to evaluate the effect of focal treatments on
disease progression in INCL. While safety and ethical issues surrounding the
use of stem cell and gene therapies remain unanswered, direct infusions of
recombinant enzyme into the CNS is a promising treatment for LSDs. Therefore,
preclinical experiments targeting the thalamus should be performed in the PPT1/- mouse to determine if a single infusion of recombinant enzyme, viral vectors, or
stem cells can significantly delay or treat the clinical features of disease.
Glial activation as a therapeutic target
Based on our findings that cytokine levels are highly elevated in both the
3KO mice and PPT1-/- brain due to glial activation, we hypothesized that
disrupting the cytokine cascade is a possible target for therapeutic intervention.
Our data demonstrate that when cytokines are increased to a certain threshold,
leukocyte entry in the CNS occurs and the disease course is exacerbated. We
observed leukocyte entry into the CNS in the 3KO mice, but not the PPT1-/mice, because of the relative cytokine elevation.
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Therefore, by keeping the

cytokine levels stable, we believe we can delay the neuroinflammatory process
response for accelerating the disease course of INCL.
Recently, the laboratory of Dr. Martin Watterson developed a novel, small
molecule called Minozac that targets the neuroimmune response generated by
astrocytes and microglia (Hu et al., 2007; Ralay Ranaivo et al., 2006). Minozac
is non-toxic, bioavailable and able to cross the blood brain barrier (BBB).

It

selectively acts on glia by knocking down pro-inflammatory cytokines that recruit
circulating immune cells into the CNS. When administered to mice, it showed
positive results in models of Alzheimer’s(Ralay Ranaivo et al., 2006),
EAE(Karpus et al., 2008), TBI(Lloyd et al., 2008; Somera-Molina et al., 2007),
and epilepsy(Lloyd et al., 2008; Somera-Molina et al., 2007), all of which present
with gliosis and neuroinflammation. In each of the four diseases, treatment of
Minozac reduced the number of activated astrocytes and microglia, decreased
cytokine levels and improved behavioral deficits. Of particular interest, in a kainic
acid-induced model of epilepsy(Tian et al., 2005), researchers demonstrated that
Minozac diminished the glial activation associated with seizure onset, which
decreased the susceptibly of mice to future seizures.

Thus, the effects of

Minozac in models of CNS disease show great promise, suggesting that Minozac
is a good candidate for treating INCL.
Combination therapy in INCL
Treatment for LSDs is as simple as it is complex. Contrary to other CNS
diseases like Alzheimer’s, Parkinson’s, or Huntington’s disease, the etiology of
INCL is known. Disease pathology in INCL is due to an enzyme deficiency and
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thus, enzyme replacement therapy rescues the deficits. Thus, in many ways, the
treatment strategies for LSDs are quite simple and unsophisticated. The problem
arises in the scope of therapy necessary to treat those afflicted with these
diseases. Contrary to other CNS disorders, the disease pathology associated
with INCL involves the entire neuraxis as well as many visceral tissues. Thus, an
effective treatment strategy must include targeting a variety of cell types in a
diverse set of tissues. It is unlikely that one therapy will be able to accomplish
this feat in isolation. Thus, we propose to use several therapies in combination
for the treatment of INCL.
The use of viral vectors to target PPT1 expression to the CNS is partially
efficacious in newborn PPT1-/- mice(Griffey et al., 2004; Griffey et al., 2005).
Although many histopathological parameters and behavioral deficits are
improved, the therapeutic benefit is only partial. Thus, future work needs to use
gene therapy in combination with other possible treatments for INCL.

For

example, Minozac, which targets the toxic effects of reactive gliosis, when used
singularly this therapy will only be partially efficacious since the primary cause of
INCL, a deficiency in PPT1, remains untreated. Therefore, treating PPT1-/- mice
with Minozac, in combination with other approaches might result in an additive or
better yet, synergistic effect in patients with INCL.
Furthermore, gene therapy and Minozac could be paired with a third drug
for the treatment of INCL. Cystagon, or phosphocysteamine, is responsible for
disrupting thioester linkages in s-acylated proteins, a similar mode of action to
the deficient enzyme, PPT1 (Lu and Hofmann, 2006; Zhang et al., 2001). In vitro
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studies

demonstrated

that

Cystagon

is

capable

of

decreasing

ceroid

accumulation in lymphoblasts from INCL patients. We have initiated preliminary
studies using once daily injections of Cystagon into PPT1-/- mice. The cystagon
treatment is non-toxic, well tolerated, and results in some clinical benefit benefit
early in disease progression. Therefore, we hypothesize that Minozac in concert
with Cystagon and gene therapy will result in an efficacious, synergistic treatment
for INCL.
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